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Background: We analyze the scientific basis and methodology used by the German MAK Commission in their
recommendations for exposure limits and carcinogen classification of “granular biopersistent particles without
known specific toxicity” (GBS). These recommendations are under review at the European Union level. We examine
the scientific assumptions in an attempt to reproduce the results. MAK’s human equivalent concentrations (HECs)
are based on a particle mass and on a volumetric model in which results from rat inhalation studies are translated
to derive occupational exposure limits (OELs) and a carcinogen classification.
Methods: We followed the methods as proposed by the MAK Commission and Pauluhn 2011. We also examined
key assumptions in the metrics, such as surface area of the human lung, deposition fractions of inhaled dusts,
human clearance rates; and risk of lung cancer among workers, presumed to have some potential for lung
overload, the physiological condition in rats associated with an increase in lung cancer risk.
Results: The MAK recommendations on exposure limits for GBS have numerous incorrect assumptions that adversely
affect the final results. The procedures to derive the respirable occupational exposure limit (OEL) could not be
reproduced, a finding raising considerable scientific uncertainty about the reliability of the recommendations.
Moreover, the scientific basis of using the rat model is confounded by the fact that rats and humans show different
cellular responses to inhaled particles as demonstrated by bronchoalveolar lavage (BAL) studies in both species.
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Conclusion: Classifying all GBS as carcinogenic to humans based on rat inhalation studies in which lung overload
leads to chronic inflammation and cancer is inappropriate. Studies of workers, who have been exposed to relevant
levels of dust, have not indicated an increase in lung cancer risk. Using the methods proposed by the MAK, we were
unable to reproduce the OEL for GBS recommended by the Commission, but identified substantial errors in the
models. Considerable shortcomings in the use of lung surface area, clearance rates, deposition fractions; as well as
using the mass and volumetric metrics as opposed to the particle surface area metric limit the scientific reliability of
the proposed GBS OEL and carcinogen classification.
Keywords: MAK, GBS, Granular biopersistent dusts, Poorly soluble dusts, OEL, Translational toxicology, Rat overload,
Inflammation, Lung cancerIntroduction
The term “translational toxicology” refers to the general
approach of applying toxicological findings to human
settings [1,2]. Here we use the term to describe the ap-
proach of using animal toxicology studies to conduct
risk assessment and hazard classifications and to derive
Occupational Exposure Limits (OELs). The latter is a
quantitative application of animal data which goes be-
yond a qualitative translation in hazard assessment. Typ-
ically, No Observed Adverse Effect Concentrations
(NOAECs) are determined in animal studies, and then
adjusted by appropriate dosimetric and/or allometric
modeling to perform a quantitative translation into Hu-
man Equivalent Concentrations (HECs). These exercises
sometimes apply various conservative assumptions that
in turn may result in very low “HECs” which are “delib-
erately” biased downward and are no longer equivalent
e.g., [3]. While translational toxicology approaches have
been around for many years [4-6], it is common to con-
sider all available data including human epidemiology data
when determining hazard classifications and OELs for po-
tentially hazardous materials. In fact, if a robust epidemio-
logical data set is available, then these results are typically
given more weight in hazard classification and OEL devel-
opment than animal toxicology studies [7].
In this paper, we analyze the scientific basis of a trans-
lational toxicology approach used by the German MAK
Commission in their recommendations for exposure
limits and carcinogen classification of “granular bioper-
sistent particles without known specific toxicity” (GBS).
Occupational exposure to inorganic dusts at concentra-
tions less than current occupational exposure limits
(OELs) can increase the risk of pulmonary disorders [8].
Particles once considered nuisance dusts and later “par-
ticles not otherwise classified” (PNOC) can cause and
aggravate a number of pulmonary disorders, including
chronic obstructive pulmonary disease (COPD) and
asthma. A recent report noted that current OELs for
these types of dusts, long considered inert, have been in
place for over 30 years and are not fully protectiveagainst potential pulmonary damage [9]. The authors
concluded that current exposure limits for these types of
dusts need to be lowered. They recommended that on
an interim basis “safety and health professionals should
consider 1 mg/m3 of respirable dust as a more appropri-
ate guideline than the value of 4 mg/m3 currently used
in Britain” [9]. We note that this publication has been
addressed by a Letter to the Editor [10].
Subsequently, the German MAK Commission issued
an OEL recommendation for respirable GBS of 0.3 mg/
m3 given a substance density of 1 g/cm3 [11]a. “The
threshold value does not apply for soluble particles, espe-
cially not for salts from rock salt and potash deposits, or
for ultrafine (see Section Vh) or dispersed coarse particle
fractions” ([12], p. 197). To derive this proposed OEL,
translational toxicology models, based on rodent data
were applied and a number of conclusions were drawn
related to the establishment of OELs and cancer classifi-
cation for GBS including those currently regulated and
those unregulated:
1) GBS cause lung cancer in rats due to chronic
inflammation as a result of dust overload in the
alveolar region of the lung.
2) If clearance mechanisms are not overwhelmed
and, thus, inflammation is prevented, lung cancer
risk will not be increased. Since excess lung cancers
in the rat are only observed in conditions of lung
overload, a threshold exists for adverse effects from
exposure to these types of dusts. Thus, a NOAEC
(no-observed adverse-effect concentration) exists;
that is, a maximum concentration greater than 0,
below which no adverse effects of GBS can be
expected, including cancer.
3) The lung overload effect observed in rat
inhalation studies is relevant for human risk
assessment. Thus, a HEC (human equivalent
concentration) exists that relates to the NOAEC,
the maximum concentration that avoids lung
overload in rats.
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threshold effect (Carcinogen Category 4).We emphasize that this cancer classification depends
on the reliability of the translational toxicology models
applied by the MAK Commission and discussed below
in detail. The MAK commission stated: “… the data ob-
tained in test animals on the potential carcinogenicity of
particles can be applied to humans if species-specific con-
ditions (anatomy and histology of the respiratory tract)
are taken into account” ([11], p. 19). (see the MAK Com-
mittee’s manifesto on the carcinogenicity classification
([11], p. 63.)
The MAK recommendations are being considered by
the Scientific Committee on Exposure Limits (SCOEL),
an advisory group to the European Commission, which
is now evaluating the potential use of these recommen-
dations for European Member States [13]. In the light of
the potential regulatory and policy implications of the
MAK guidelines, we examined the scientific studies and
assumptions that were used as the basis of the proposed
exposure limit. Two fundamental approaches were
chosen [11]: one based on retained particle mass per al-
veolar surface area (Model A) and another based on
retained particle volume per macrophage pool volume
(Model B, [14]) in rat inhalation studies, investigating
the effect of dust exposure on inflammatory markers.
These approaches were used to estimate the HEC. As a
compromise between 0.15 mg/m3 and 0.25 mg/m3 (HEC
according to Model A) and 0.5 mg/m3 (HEC according
to Model B), an OEL was recommended for the respir-
able fraction of 0.3 mg/m3 for GBS with a particle dens-
ity of 1 g/cm3. This value replaced the previous general
dust limit for the respirable fraction of 1.5 mg/m3 [15].
Because the above considerations only apply to the res-
pirable fraction, the former general dust limit for the
inhalable fraction of 4 mg/m3 [15] remains valid.
The derived MAK OEL for respirable GBS is solely
based on the quantitative translation of rat overload ex-
periments into HECs without any consideration given to
human epidemiological studies. This new MAK ap-
proach is a substantial departure from principles that
have been used for many years in including results of
human studies, most notably epidemiological investiga-
tions. To rely so heavily on translational toxicology
models only, the new approach must be transparent,
consistent, and evidence-based.
The purpose of our analyses is to review the recom-
mendations for GBS by examining the scientific assump-
tions used by the MAK Commission. We have
attempted to reproduce the derivations and recalculate
the results by employing the translational toxicology
methods used for Model A and Model B [14].Use of models as suggested by the MAK
commission
The German MAK Commission [11] proposed two pro-
cedures (Model A and Model B) to estimate a no-
observed adverse-effect concentration (NOAEC) for the
respirable dust fraction of GBS in rats and to translate
this value into a HEC. When we tried to apply the
Models A and B we discovered a number of numerical
problems. In the following Section we present, analyze
and discuss Model A ([11], p. 54–58).
Model A: The retained particle mass per alveolar
surface area model
Model A assumes one lung compartment (alveolar) and
a constant (species-specific) alveolar clearance rate
below the overload effect. The input into the alveolar
compartment is determined by the particle deposition
rate in the alveolar region [mg/day]. The output from
the alveolar compartment can be expressed as the par-
ticle burden in the alveolar region [mg] x alveolar clear-
ance rate [1/day]. Given steady state we have input =
output, i.e., deposition = steady-state burden x clearance
rate. It follows that:
Steady state particle mass burden in the alveolar re-
gion [mg] = particle mass deposition rate in the alveolar
region [mg/day]/alveolar clearance rate [1/day].
Particle mass deposition rate in the alveolar region
[mg/day] was defined as dust concentration in inhaled
air [mg/m3] x alveolar deposition fraction [%] x tidal vol-
ume [m3 per breath] x respiratory rate [breaths per day].
The alveolar deposition fraction was calculated for rats
and humans by applying the MPPD (multiple-path par-
ticle dosimetry) Version 2.0 program (see for informa-
tion on the MPPD: de Winter-Sorkina and Cassee [16]
and http://www.ara.com/products/mppd.htm). The con-
stant alveolar clearance half times are assumed to be
60 days for rats and 400 days for humans. Based on these
assumptions and other input data, the steady state particle
mass burden in the alveolar region is calculated for rats at
the maximum exposure concentration when they showed
no inflammation/overload according to Muhle et al. [17]
who studied the effect of toner particles and pigmentary
titanium dioxide (TiO2) particles: NOAECtoner: 1 mg/m
3
respirable and NOAECTiO2: 5 mg/m
3 respirable.
These amounts of retained dust masses are the “numer-
ator” of the metric in the particle-mass lung-surface
model. When converting from rats to humans, the ratio of
the “numerators” and the ratio of the alveolar lung sur-
faces are taken into account (ratio of “denominators”).
Model A is based on the metric “retained particle mass
per lung surface area”. The working assumption in
Model A is that the effect of the dust is species-
independent, when described on the scale of the
“retained particle mass per lung surface area” metric.
Table 1 Alveolar deposition fractions calculated with
MPPD, Version 2.0








Results are shown for toner [17] with a true density of 1.2 g/cm3 and varied
densities from 1 g/cm3 up to 5 g/cm3 while keeping all other input data
constant. The range includes the density of TiO2, 4.3 g/cm
3.
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of the two species, rats and humans does not differ at the
same dose/m2 lung surface area” ([11], p. 54). The foot-
note on page 56 of [11] clarifies that the numerator (i.e.,
the dose) is the retained particle mass and not particle
volume or particle surface area: “The inhaled particle
concentration and the deposited/retained particle dose
were determined as particle mass in the studies and were
also included in the calculation as particle mass”. This
concept that a given mass of a substance acting on a
unit area of lung tissue generates the same qualitative
and quantitative effect in the lung across species is de-
scribed as one possible application in Oller and Oberdörster
[18], Figure One: retained accumulated doses in μg/cm2 yield
similar health effects in rats and humans (although not ap-
plied in this example to GBS but to soluble materials). The
metric of Model A is mentioned additionally by a working
group of the U.S. EPA: “alveolar mass per alveolar surface
area” [19]. Based on this metric, the MAK Commission [11]
used the rat experiment data of Muhle et al. [17] to derive
HECs for toner and TiO2 by translational toxicology.
Model A leads to HECs of 0.133 mg/m3 (toner) and
1.02 mg/m3 (TiO2). Next, the MAK Commission applied
a density division and derived a generic HEC (respirable)
of about 0.15 mg/m3 to 0.25 mg/m3 for a substance
density of 1 g/cm3 (0.133/1.2 = 0.11; 1.02/4.3 = 0.24).
We note that the rat NOAECs were 1 mg/m3 (toner)
and 5 mg/m3 (TiO2). In light of the attained HEC values,
this means that humans are more sensitive to inflamma-
tion/overload than rats on the mg/m3- exposure scale
according to this calculation.
In the following, we present arguments and discuss
the shortcomings of the Model A. In particular, we high-
light the followingb:
 The post-hoc density adjustment of the derived
HEC values is inconsistent and not justified,
 The lung surface area values used in the calculations
are not evidence based,
 The alveolar clearance rate chosen for humans can
be disputed according to current research.
Model A: Inconsistent post-hoc density adjustment
Applying the “retained particle mass per lung surface
area” metric, the MAK Commission [11] derived HEC
values for toner and TiO2. After arriving at these values,
a post-hoc correction of the derived HECs was per-
formed by dividing the values with the respective dens-
ities of toner and TiO2. The Commission [11] states:
“The first derivation yields for toner a limit value of
0.133 mg/m3 (density 1.2) and for titanium dioxide a
value of 1.06 mg/m3 (density 4.3) or for a density of 1, a
value of 0.11 mg/m3 for toner and 0.25 mg/m3 for titan-
ium dioxide” (p. 63). We note that the units for thedensities are omitted (e.g., “density 4.3” should read “dens-
ity 4.3 g/cm3”). Thus, if the division is performed with
units, one gets: 1.06 mg/m3/4.3 g/cm3 = 0.00000000025
(=2.5 × 10−10). Note that the units cancel out and the re-
sult has no units. Given that the final result of the deriv-
ation process should represent a concentration (HEC), it
must be expressed with units, namely “mg/m3”. This is
not the case with Model A, if values are computed cor-
rectly. In addition, we note that the correct value is 9 or-
ders of magnitude lower than the MAK-derived value of
0.25 mg/m3 as given in [11].
In the following, we will show that the assumptions
and equations of Model A imply that a density depend-
ency of the NOAEC is logically ruled out. Thus, the
post-hoc performed division of the HEC by the sub-
stance density contradicts the core principles of Model
A. We explain this substantial problem in detail below.
The MAK Commission [11] calculated the alveolar de-
position fraction of particles with the multiple-path par-
ticle dosimetry (MPPD) program, Version 2.0 (see for
information on the MPPD: de Winter-Sorkina and Cassee
[16] and http://www.ara.com/products/mppd.htm). Using
the same version of the MPPD program as used in [11],
we simulated a run where particle distribution and con-
centration are kept constant while substance densities
are varied. The results shown in Table 1 demonstrate
that the alveolar deposition fraction does not largely
depend on the substance density if the same particle
distribution and the same concentration are applied in
two experiments with substances of different densities.
We note that there is some marginal dependence, but
this is in the opposite direction: substances with higher
density have a somewhat larger deposition fraction,
and not a smaller deposition fraction as would be
needed to justify the density division performed in
[11]. Conservatively, we assume in the following that
the alveolar deposition fraction is independent of the
substance density.
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on elimination (alveolar clearance). The basic equation
(1) on page 54 in [11]
steady state lung load ¼ mean deposition rate=clearance
ð1Þ
describes a one-compartment model with a constant
clearance rate. A constant alveolar clearance rate means
that per time unit, identical percentages of the deposited
particles (number, mass, volume) will be eliminated from
the alveolar region (we note that this means that equa-
tion (1) rules out an elimination of identical masses per
time unit). This interpretation is in agreement with the
term “elimination half time” used in [11]: see equation
(4) on page 55. According to the findings described in
Bellmann et al. [20], Muhle et al. [17] and Pauluhn [14],
MAK applied identical elimination half times in rats of
60 days for toner and TiO2 despite the different densities
of both substances (see for toner equation (5) on page
55 and the calculation for TiO2 on page 57 in [11]). The
implication is that, besides the particle deposition frac-
tion, particle clearance is also independent of “density”.
Given that identical masses are deposited (as we have
shown in Table 1) and that the elimination half time of
alveolar clearance does not vary with substance density
as inferred in the use of an identical elimination half
time in rats of 60 days for toner and TiO2 by the MAK
Commission, equation (1) implies that identical masses
will be retained for toner and TiO2. The effect metric of
Model A is “retained particle mass per alveolar surface
area“, meaning that equal masses of two different sub-
stances independent of their densities, acting per unit
area of lung tissue should trigger the same effect. It thus
follows that the HEC must be density independent. In
conclusion, the post-hoc density correction of the HEC
contradicts the basic assumptions of Model A.
The MAK Commission justifies the density correction in
[11] as follows “even though the dose deposited per m2 lung
surface area is calculated in procedure A, macrophage-
elicited alveolar particle clearance has to be considered in
the chronically retained particle dose; the particle density/
particle volume is also relevant for this particle clearance in
procedure A. Therefore, the particle density has to be taken
into account in procedure A” ([11], p.53). This rationale,
however, implies that the effect metric has been changed
and that the retained mass per surface area is no longer the
only and most critical measure. Again, this conflicts with
basic assumptions of Model A to translate the rat study
findings to humans by a comparison of lung surface areas.
Moreover, following the logic for density correction pro-
vided above, one should expect varying elimination half
times for TiO2 and toner assuming a difference in the dens-
ity dependent alveolar clearance rates between TiO2 andtoner by a factor of 3.6 (because the ratio of the densities is
4.3/1.2 = 3.6). Experimental findings however report to the
contrary [14,17,20].
Based on the arguments provided above, we conclude
that the performed post-hoc density correction is unjus-
tified and should be eliminated to achieve a consistent
Model A.
Model A: Lung surface area values used by MAK are not
derived using contemporary recognised standard
procedures endorsed by the American Thoracic Society and
the European Respiratory Society
Model A assumes that “the sensitivity of the two species
rats and humans does not differ at the same dose/m2
lung surface area” ([11], p. 54]). Thus, to translate find-
ings from rat studies into HECs, the lung surface areas
of both species have to be taken into account. MAK
used “an alveolar surface area of 57.22 m2 for humans
and 0.297 m2 for rats” ([11], p. 54). This leads to a sur-
face area ratio (i.e. translation factor) of 57.22/0.297 =
193. These alveolar surface area values are taken from
Table Five in Brown et al. [5]. The numbers were also re-
ported in US EPA [21] but no longer in the updated
document [22]. Unfortunately, the values presented in
Brown et al. [5] cannot be reproduced because the basic
data and the calculations are not given. Brown et al. [5]
referenced Yeh et al. [23] who reported on one Long-
Evans rat (not Fischer rats) and the authors referenced
Yeh and Schum [24] who studied one man. First, we
note that when studying the effects of toner and TiO2,
Muhle et al. [17] used Fischer rats (F344) in their re-
search and this paper formed the basis of the MAK
Commission’s HEC derivation in Model A. However, “for
interspecies dosimetric adjustments when translating ani-
mal toxicological study results obtained in rats to judge
the potential for effects to be seen in humans, dosimetry
calculations should be done using strain specific lung
geometries” [25]. Second, the method applied by Yeh
et al. [23] and Yeh and Schum [24] (silicone rubber cast
with added mathematical extrapolations) does not fulfil
the conditions of the reference procedure defined jointly
by the American Thoracic Society and the European Re-
spiratory Society of how to measure lung surface areas
[26]. The standard method, however, was applied in
Gehr et al. [27] (on 8 humans) and in Stone et al. [28]
(on 4 Fischer rats, i.e., the rat strain of interest). Accord-
ing to these standard procedure measurements, the best
alveolar surface area estimates are 143 m2 (human) and
0.41 m2 (F344 rat), leading to a ratio of 349 = 143/0.41.
We note that Stone et al. [28] reported on human sur-
face areas also, but the measurements were based on
surgically resected lung lobes (not an in situ instillation).
Thus, an underestimation of the true surface areas is
probable because of a post-mortem atelectasis and the
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[27]. An overview is given in Table 2.
The lung surface area data of Gehr et al. [27] are pub-
lished in an often cited text book on comparative biology
[29]. EU institutions recognise and refer to these values
in their documents: “over the huge alveolar surface area
of 150 m2, the deposited particles are separated from the
capillary blood by a tissue barrier” ([30], p. 24). This
value is also recognised by the International Commission
on Radiological Protection (Human Respiratory Tract
Model, [31]). MAK based the Model A calculations on
the MPPD 2.0 deposition model. It is important to note
that even the authors of the MPPD program used the
lung surface area data of Gehr et al. [27] in their applica-
tions [16]. Thus, the results of Gehr et al. [27], obtained
with standard procedures [26], are widely recognised
and used as the reference for the human lung surface
area. The MAK Commission dismissed the value from
Gehr et al. [27] arguing that: “the author himself points
out that the true values may range between 70 and
100 m2” ([11], p. 55). Apparently, the MAK Commission
appears to have misinterpreted the work of Gehr et al.
[27], who stated on page 136: “we have shown on rat
lungs that the ‘true’ alveolar surface available for gas ex-
change must be 25-50% smaller than the epithelial sur-
face, depending on the level of air space inflation.… If
this is taken into consideration the ‘true’ alveolar surface
of the human lungs included in this study is reduced to
70–100 m2”.
It is clear that Gehr and colleagues [27] discussed the
surface available for gas exchange and not the epithelial
surface. We note that the latter is relevant as the de-
nominator in Model A’s metric. Furthermore, Gehr et al.
[27] discussed the variation of the alveolar surface area
in dependence on the air space inflation and Gehr’s ar-
gument relies on the assumption mentioned in [27] that
the ratio between human and rat lung surfaces do not
vary with air space inflation. Thus, the derived ratio of
349 remains valid irrespective of what degree of air
space inflation is assumed to define ‘true’ values.
In summary, by using rat and human lung surface area
data determined by internationally recognised methods,
we have derived a translation factor of 349 which is
about 1.8 fold higher than the MAK derived value of 193
[27,28]. We thus conclude that the MAK Commission
[11] did not use the data best available on alveolar surface
areas to derive the translation factor from Fischer rats to
humans.
Model A: The alveolar clearance rate chosen for humans
can be disputed according to current research
The applied value for the human alveolar clearance half
time of 400 days is too large in comparison to current
estimates of 255 days [32]. Current estimates were basedon a two-compartment model that distinguishes the
bronchiolar and interstitial region as target compart-
ments of the alveolar region. The model was originally
developed by Kuempel et al. [33] to predict lung and
lymph node particle retention in US coal miners.
Gregoratto et al. [32] adapted this model to amend the
Human Respiratory Tract Model of the International
Commission on Radiation Protection (ICRP) [31] and
the authors validated this model with new human data
from three studies of people exposed to radioactive aero-
sols, e.g. teflon particle and cobalt exposure. The model
structure was recently adopted by the ICRP to describe
the long-term particle clearance and retention of parti-
cles in the alveolar-interstitial region of the human re-
spiratory tract [34]. The applied value of 400 days
ignores a clearing of the particles from the human alveo-
lar region into the interstitium, a critique also made by
ECETOC ([34], Section 2.3, p. 17). Importantly, the
comparative anatomical/histological study of Nikula and
coworkers [35] on lungs of rat and human loaded with
particulate matter corroborates the fundamental differ-
ences of clearance dynamics between both species (see
also the Section on species-specific responses below).
In addition, a value of about 250 days follows from the
general allometric scaling procedure proposed by West
et al. [36]. We applied this independent approach based
on allometric scaling to estimate the ratio of rat and hu-
man alveolar clearance rates (and half times). For ex-
trapolation of the rat alveolar clearance rate krat to a
human alveolar clearance rate khuman, an allometric scal-
ing according to West et al. [36] should yield
khuman ¼ krat
 bodyweightrat=bodyweighthumanð Þ1=4:
Given a clearance half time of 60 days and a body-
weight of 250 g for the rat we derive as an estimate for
the human alveolar clearance half time, assuming a
weight of 70 kg: 60 days/[(0.25 kg/70 kg)(1/4)] = 245 days
(we note that we discuss half times which are indirectly
proportional to rates: half time = ln(2) / rate). This calcu-
lation, according to West et al. [36], supports the value
of 255 days proposed by Gregoratto and colleagues [32].
If a larger bodyweight of 330 g is chosen for the rat, the
estimated human half time will be 230 days.
Model A: Outcome on the HEC estimates
Assumptions made in a derivation process clearly affect
the resulting value of any derived OEL. In this subsec-
tion, we want to demonstrate the range of values that
can occur and how different these values are from the
MAK-derived values when internationally standardized
data for pulmonary clearance and lung surface area are
used.
Table 2 Alveolar surface areas in rats and humans (the toxicological study [17] applied in model A used Fischer rats F344)






Yeh [23] Rat (Long Evans,
330 g)
1 silicone rubber cast (does
not entail the alveolar region)
TLC 0.5725 m2 (mentioned
as calculated value
on p. 487, no value given
in Table Two)
- -
Yeh & Schum [24] Human (60 years, ♂) 1 silicone rubber cast (does
not entail the alveolar region)
TLC No value given (neither
in the text nor in Table Two)
- -
US EPA [21]
Brown et al. [5]
Rat (authors reference
Yeh et al. [23], scaled
to FRC) human (authors
reference Yeh and Schum
[24], scaled to FRC)
1 silicone rubber cast (does not
entail the alveolar region)
derivation of values in Brown
et al. [5] cannot be
reproduced from Yeh et al.
[23] and Yeh and Schum
[24] because of missing data
and an unknown algorithm
FRC 0.2972 m2 193 (57.22/ 0.2972)
1 FRC 57.22 m2




according to the reference
method, Hsia et al. [26])
TLC 143 m2 ± 12 349 (143 acc. to Gehr/0.41
acc. to Stone) (identical
methods and F344 rats)




according to the reference
method, Hsia et al. [26])
TLC 0,41 m2 ± 0,04 249 (102,2/ 0,4)
0.4 m2 ± 0,03Rat (SD, 363 g) 8
Human (nonsmoker) 4 (3♀, 1♂) surgically resected lung




102.2 m2 ± 20,5
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above the ratio of the alveolar surface areas according to
Gehr et al. [27] and Stone et al. [28] is 349. The Com-
mission [11] applied a ratio of 193, which leads to a cor-
rection factor of 1.81 = 349/193. The alveolar clearance
half time according to Gregoratto et al. [32] is 255 days.
MAK [11] applied 400 days. This leads to a second cor-
rection factor of 1.57 = 400/255.
Using the correction factors for clearance rate and
lung surface area, the following estimates for HEC de-
rived with Model A are obtained:
HECtoner ¼ 0:134 1:81 1:57 mg=m3
¼ 0:38 mg=m3
HECTiO2 ¼ 1:07 1:81 1:57mg=m3 ¼ 3:04 mg=m3
These estimates should also apply for a substance
density of 1 g/cm3 because the HEC is independent of
density according to the fundamental assumptions of
Model A. The large range of the HEC estimates seen
above shows that Model A is not appropriate for deriv-
ing a generic OEL for all GBS.
Model B: The retained particle volume per macrophage
pool volume model
MAK’s Model B is another approach proposed to estimate
a no-observed adverse-effect concentration (NOAEC) for
the respirable dust fraction of GBS in rats and to translate
the estimated NOAEC into a HEC. Model B is based on
the publication of Pauluhn [14]. The specific metric of
Model B - different from Model A’s metric - is assumed to
be species-independent: the retained particle volume per
alveolar macrophage pool volume [14].
Like Model A the retained particle volume per alveolar
macrophage pool volume [14] model assumes one lung
compartment and a constant (species-specific) alveolar
clearance rate below the overload threshold. Because
Model B focuses on the volume of the particles the units
change from mg to μl (compare the Section on Model
A): steady state particle volume burden in the alveolar
region [μl] = particle volume deposition rate in the alveo-
lar region [μl/day]/alveolar clearance rate [1/day].
The particle volume deposition rate in the alveolar re-
gion [μl/day] is calculated as dust concentration in in-
haled air [mg/m3]/density [g/cm3] x alveolar deposition
fraction [%] x tidal volume [m3 per breath] x respiratory
rate [breaths per day]. We note that in contrast to
Model A, the particle density is a necessary term in this
equation, and HECs derived by Model B will be density
dependent. We further note that the units are consist-
ent: μl x g/cm3 = 10−6 × 103 cm3 × g/cm3 = 10−3 g =mg.It follows that a rat NOAEC in mg/m3 can be esti-
mated as:
{steady state particle volume burden in the alveolar re-
gion [μl] x density [g/cm3] x alveolar clearance rate [1/
day]}/{tidal volume [m3 per breath] x respiratory rate
[breaths per day] x alveolar deposition fraction [%]}.
This justifies the structure of the important Equation
(7) in [14], reproduced in [11] on page 59. Pauluhn [14]
derived a factor of 1 to translate the rat overload
NOAEC into a HEC (i.e., according to Model B rats and
humans are of the same sensitivity on the mg/m3-exposure
scale). Finally, Model B leads to
HEC mg=m3
  ¼ 0:5  particle density g=cm3 
Model B is used in two derivations: the first relies on a
Fortran program written by Prof. Dr. Jürgen Pauluhn,
the second derivation can be performed without apply-
ing this program. The second derivation was used by the
MAK Commission to derive an occupational limit value
for all GBS ([11], p. 58–62). This volumetric approach
has also been applied to biodegradable high molecular
weight organic polymers [37].
We highlight the followingc:
 The first derivation cannot be verified by
an external reviewer because of unavailable
information (i.e. the inaccessibility of the
Fortran program),
 The standardization to rat lung mass or to rat body
weight is varying and inconsistent,
 The deposition fractions applied cannot be
reproduced with the cited MPPD program
using the input parameters listed in [11],
 Assumptions used for the alveolar clearance rate for
humans are incorrect and not based on the best
available current research.
Below, we analyze the impact of these 4 points on the
estimated HEC.
Model B: Non-replicable method applied for the calculation
of the NOAEC in the first derivation
The first approach introduced in [14] describes the der-
ivation of a volumetric NOAEC. This derivation relies
on the Fortran program code with an unknown algo-
rithm: “A Fortran computer code was used for calcula-
tions” ([14], Section 2.7, p. 182). The Fortran program
was briefly described on page 142 in [38]. The code
seems to estimate the daily increment of particle dose
deposited in the alveoli using data from the multiple-
path particle dosimetry model (MPPD, http://www.ara.
com/products/mppd.htm) to calculate the fate of the de-
posited particles by applying elimination rate constants,
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retained particle burden. Because the code incorporates
output data from the MPPD program, the derivation of
the NOAEC based on the Fortran program likely suffers
from the shortcomings detailed in Section on the depos-
ition fractions below.
We reconstructed in Table 3 the chain of arguments as
used in the first derivation and refer mainly to the 3rd para-
graph of the Section on lung overload on page 181 in [14].
The respiratory volume of rats was calculated as 6 h ×
60 min/h × 0.8 l/min/(day x kg-rat) = 288 l/(day × kg-
rat) = 0.29 m3/(day × kg-rat). This number refers to a
(theoretical) rat of 1 kg mass. Physiological dead space,
assumed as 1/3 of the total inhaled volume, was used to
estimate the alveolar ventilation volume of 0.19 m3/(day ×
kg-rat) on the basis of the respiratory volume: 2/3(0.29)
m3/(day × kg-rat) = 0.19 m3/(day × kg-rat). Next, a critical
particle volume in the rat’s alveolar space was calculated
by the Fortran program code as 0.069 μl/day [see Figure
Three in 14] (note that the caption to the figure confus-
ingly uses different units: 0.069 μl/m3 - micro liters per
cubic meter as opposed to micro liters per day). The de-
rived concentration in the rat’s alveolar volume of
(0.069 μl/day)/(0.19 m3/day) = 0.36 μl/m3 was then used to
calculate a corresponding respirable particle volume con-
centration in the inhaled air of 0.36 μl/m3 × 3/2 = 0.54 μl/
m3. This figure represents the volumetric NOAEC, i.e., the
maximum volume concentration that rats can inhale
without becoming overloaded. “The 2-year equivalent
is 0.069 μl PMresp/0.19 m
3
alv or 0.36 μl PMresp/m
3
alv (see
Figure Three). In terms of inhalation chamber concen-
trations and exposure durations (adjustment from al-
veolar ventilation to normal ventilation) this means
that the above generic volumetric overload-threshold is
attained when using daily exposure concentrations at …
0.54 μl PMresp/m
3 for…chronic repeated inhalation ex-
posures” ([14], p. 181). Apparently, a factor of 3/2 was
applied to convert PMresp/m
3
alv to 0.54 μl PMresp/m
3.
This factor likely reflects a correction due to the de-
position of the dust in the head and tracheo-bronchial
region of the rat which was calculated using the MPPD
Version 2.0. Applying the input parameters listed in
the MAK document (including the “inhalabilty adjust-
ment”, see ([11], p. 52) we calculated a deposition frac-
tion in the head and tracheo-bronchial region of 25%.
This would lead to a correction factor of 1/(1–0.25) =
4/3. In Pauluhn [14], a factor of 3/2. was used; MPPD
2.0 returned a deposition fraction of 1/3 (33%) if we
choose the default option of the program and turned
the “inhalability adjustment” to off. This would lead to
an adaptation factor of 1/(1-1/3) = 3/2, which is identi-
cal to the value noted in Pauluhn [14].
We conclude that the calculations shown in Pauluhn
[14] were performed with the default option of theprogram, without an application of an “inhalability ad-
justment”. Unfortunately, such important details are not
documented in the publication and the author has not
responded to our request for clarification (see Endnote 3).
The “inhalability adjustment” is a recommendation made
in the MAK document for calculating deposition fractions
in rats with the MPPD program ([11] p. 58). Oller and
Oberdörster [18] also made this recommendation.
We will analyze and discuss further problems encoun-
tered in replicating the deposition fractions applied in
Model B calculations in more detail below (see the
Section on the deposition fractions). We would like to
emphasize, however, that the calculated value of
0.069 μl/day is a pivotal input to the first derivation of
the NOAEC and relies solely on the unavailable Fortran
code. Thus, it is unclear, if and how this analysis can be
reproduced for verification.
Model B: The standardization by rat lung mass or rat body
weight is varying and inconsistent
In Pauluhn [14] a second approach to estimate a NOAEC
was suggested (see p. 181 and 182). Basic assumptions
include:
 The number of alveolar macrophages was given as
6 × 107/kg-rat and
 The volume of the alveolar macrophage of the rat as
1166 (μm)3 (see Table Two and the 3rd paragraph of
the Section on lung overload on page 181 in [14]).
This leads to a volume of the alveolar macrophage
pool of 6 × 107 × 11.66 x10−7 μl/kg-rat = 70 μl/kg-rat [1
(μm)3 = 10−18 m3 = 10−15 l = 10−9 μl].
 Morrow’s original overload volume threshold [39]
was set to 6% of the alveolar macrophage pool
volume: 6% × 70 μl/kg-rat = 4.2 μl/kg-rat.
 The mass of the lung of a 330 g rat is given as 1.5 g
in Table Five of Brown et al. [5], referring to
Takezawa et al. [40]. Accordingly, Pauluhn [14]
stated on p.181 “4.5 g lung weight per kg-rat”.
Thus, Morrow’s overload volume threshold can also be
expressed as 4.2 μl/4.5 g-rat lung = 0.93 μl/g-rat lung,
i.e., as a value of about 1 μl/g-rat lung.
To assess the corresponding overload concentration
threshold in the chamber air (NOAEC), this second ap-
proach took into account the alveolar deposition fraction
in rats calculated by MPPD and assuming an equilib-
rium (steady state) of deposition and clearance: see
Equations (6) and (7) on pages 181 and 182, respectively
in [14]. Equation (7) is of major importance because it
yields the NOAEC, called NO(A)EL (predicted) in [14].
This equation is reproduced in [11] on page 59:
Table 3 First volumetric approach to derive a NOAEC in rats (3rd paragraph of the section on lung overload on page 181 in Pauluhn [14]), all data are relative
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Equation (7) starts with the fraction 1 μl/0.29 m3. We
note that 1 μl represents Morrow’s overload volume
threshold expressed as 1 μl per g-lung whereas 0.29 m3
means the respiratory volume of 0.29 m3 per kg-rat. Ob-
viously, units are confused and Morrow’s overload
threshold should also refer to a 1 kg rat and, thus,
should have been set to 4.2 μl per kg-rat in Equation (7).
This correction increases the estimated NOAEC by a
factor of 4.2.
Model B: Deposition fractions applied in Pauluhn [14]
cannot be reproduced with the MPPD program given MAK’s
input data [11]
Equation (7), p. 182 ends with the term 100/PMresp.,
which is the inverted alveolar deposition fraction be-
cause PMresp denotes the deposition fraction in %.This
notation is confusing: the author wrote in other places
“Fa = fractional deposition of PM in the alveolar region,
PMresp, as estimated by MPPD2 calculations” (p. 181/
182 and 186) so that Fa is the deposition fraction and
PMresp means the “pulmonary deposited dose ‘PMresp’…
estimated by MPPD2 calculation” (p.182). Nonetheless,
the alveolar deposition fraction is of importance in the
estimation of the NOAEC and this fraction was set to
7.5% ([14], p. 186). The MAK Commission [11] stated
that Pauluhn [14] and the MAK Commission deter-
mined the alveolar deposition fractions with the help of
MPPD Version 2.0. We applied this program version but
calculated a fraction of 6.3%. According to the current
MPPD Version 2.11 it is even lower, only 3.3%. To per-
form these calculations, we used input data taken from
[14] (mass median aerodynamic diameter: MMAD =
1.8 μm, geometric standard deviation: GSD = 2, particle
density = 1 g/cm3, p. 186) and the MPPD parameters as
published in Table Four of Oller and Oberdörster [18]
and, accordingly, in the MAK document [11]. Thus, it is
unclear why a value of 7.5% was reported in [14] (Equation
8) and ([11], p. 61). Even larger problems arose when we
tried to reproduce the alveolar deposition fraction in
humans of 16.4% as applied in [14] (Equation 8) and by
the MAK Commission ([11], p. 61): we arrived at a value
of 8.4% with MPPD Version 2.0 and 8.8% with the current
MPPD Version 2.11. Likewise, we could not replicate the
substance specific deposition fractions in Table One of
[14]. These problems also affect the adaptation factor
AFlung burden because it entails the ratio of the rat and hu-
man alveolar deposition fractions (see Equation (8) on
p. 186 in [14]). For a more complete discussion and a po-
tential explanation of the differences see the Section on
our sensitivity analysis below.We emphasize that a revision of the deposition calcu-
lations in [14] and [11] is needed because the deposition
fractions were calculated with an MPPD version (i.e.
MPPD Version 2.0) that is outdated. Hence the calcula-
tions of the MAK Commission are not based on a state
of the art technique. We note that the outdated MPPD
Version 2.0 is no longer publicly accessible to enable an
independent reviewer to reproduce the results. Fortu-
nately, one of the co-authors of this review has a copy of
the outdated version which we used for our calculations.
Model B: The alveolar clearance rate chosen for humans is
incorrect and needs revision based on recent research
The applied value for the human alveolar clearance half
time of 400 days is too large in comparison to current
estimates of 255 days [32]. The value of 400 days ignores
a clearing of the particles from the human alveolar re-
gion into the interstitium, a critique also made by ECE-
TOC ([34], Section 2.3, p. 17). In addition, a value of
about 250 days follows from the general allometric scal-
ing procedure proposed by West et al. [36], (see the
Section on alveolar clearance rates in Model A above).
Model B: Sensitivity analysis: Deposition fractions and
NOAECs
We evaluated the impact of some of the issues identified
above and present the findings in Table 4. Only the sec-
ond derivation, based on Equation (7), ([14], p. 182), can
be analyzed because we could not obtain the Fortran
program to do a sensitivity analysis of the first NOAEC
derivation. We note that Equation (7) implicitly used an
alveolar clearance rate in rats of 0.01/day that is not in-
dicated. This is confusing because the equation should
show all variables that have to be taken into account to
evaluate Equation (7).
The first line of Table 4 repeats the calculations with
input values as noted in [14]. The calculated NOAEC,
the calculated adaptation factors and the overall finding
of an estimated HEC = 0.53 mg/m3 agree with the results
shown in [14]. One striking difference in all calculations,
however, is the lower alveolar deposition fraction in
humans: 16.4% in the first line but values between 8%
and 9% in all other scenarios. The reason for this discrep-
ancy is one different MPPD input parameter value: “Oro-
nasal-Normal Augmenter” is chosen to characterize the
breathing pattern in humans in all lines but the first where
we used “Oronasal-Mouth Breather”. We emphasize that
“Oronasal-Normal Augmenter” is a recommendation made
in the MAK document ([11], p. 58 and Appendix). Indeed,
for humans, the MAK Commission has published in other
applications alveolar deposition fractions that are similar to
our values (Table 4): 7.01% for toner dust and 8.72% for
TiO2 dust using the substance data as given in Muhle et al.
([11], p. 56, 57, 17). Furthermore, the recommendation
Table 4 Sensitivity of results in dependence on modified input data (MPPD input parameters, steady state particle volume, clearance half time in humans) and
different MPPD program versions: Estimated NOAEC in rats, calculated adaptation factors AFlung burden and AFclearance, and the derived human equivalent
concentration (HEC) according to the second Model B procedure described by Equation (7) on p.182 and Equations (8), (9), (10) on p. 186 in [14]
MPPD
Version



















AF lung burden/1 AF clear ance/1 HEC/mg/m
3
2.0 IA switched off OMB 7.5 16.4 1 400 0.53 0.93 0.93 0.53
2.0 IA ONA 6.3 8.4 1 400 0.63 1.52 0.93 1.03
2.11 3.3 8.8 1 400 1.21 0.76 0.93 0.98
2.0 IA ONA 6.3 8.4 4.2 400 2.66 1.52 0.93 4.33
2.11 3.3 8.8 4.2 400 5.07 0.76 0.93 4.14
2.0 IA ONA 6.3 8.4 1 250 0.63 1.52 0.58 1.65
2.11 3.3 8.8 1 250 1.21 0.76 0.58 1.58
2.0 IA ONA 6.3 8.4 4.2 250 2.66 1.52 0.58 6.93
2.11 3.3 8.8 4.2 250 5.07 0.76 0.58 6.62
*IA, Inhalability Adjustment; OMB, Oronasal-Mouth Breather; ONA, Oronasal-Normal Augmenter; Other input data used invariantly and in accordance with [14] and [11]: reference body weights = 1 kg-rat, 70 kg-human;
ventilation rates = 0.29 m3/kg-rat and day, 10 m3/70 kg-human and day; macrophage pool volumes = 7x1010 μm3/kg-rat and 50x1010 μm3/kg-human; alveolar clearance half time in rats = 60 days; MMAD = 1.8 μm,
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text of MPPD 2.11. The tutorial states: “Choose Oronasal-
Normal Augmenter so as to perform the calculation for oro-
nasal breathing for the normal case for which nasal breath-
ing occurs under minute volumes of 35.3 L/min, but
switches to combined nose and mouth breathing above this
value” (MPPD 2.11 Tutorial 2: Monodisperse for Human,
http://www.ara.com/products/mppd.htm). Oller and Ober-
dörster [18] have also made this recommendation. In con-
trast, in Pauluhn [14] the breathing pattern chosen was
“oronasally breathing humans” (p. 186). When we, how-
ever, interpreted this as the program option “Oronasal-
Mouth Breather”, MPPD 2.0 returned a deposition fraction
of 16.4% identical to that reported in [14]. We would like
to note that MPPD 2.11 gave a similar value of 15.7% when
choosing “Oronasal-Mouth Breather”, and that the human
deposition fractions are comparable when calculated with
MPPD Version 2.0 or 2.11. The MPPD Help function clari-
fies on Oronasal-Mouth Breathers: “Habitual Mouth
breathers are considered to breathe through the nose and
mouth simultaneously, even at rest”.
We conclude that Pauluhn [14] probably chose “Orona-
sal-Mouth Breather” to characterize the breathing pattern
in humans, instead of “Oronasal-Normal Augmenter”, the
recommendation of MAK and MPPD. Thus, the calcula-
tions in [14] seem to suffer from a divergent setting of
MPPD input parameters on breathing patterns in humans.
Furthermore, the MPPD 2.0 applications in Model B, as
performed by the MAK Commission [11], are inconsistent
and confusing.
Another noteworthy difference among the programs is
the lower (~50%) alveolar deposition fraction in rats of
3.3% calculated by the current program (MPPD 2.11) in
comparison to 6.3% (MPPD 2.0). This figure reflects true
differences between program versions because the find-
ings are based on identical input data. We can reproduce
the value of 7.5% published in Pauluhn [14] if we switch
off the “inhalability adjustment” in MPPD 2.0. The
MPPD tutorial explains: “Choose whether the program
should adjust for inhalability of the aerosol using logistic
functions suggested by Menache et al. [41] for small la-
boratory animals. For small particles, this inhalability is
unity. By default, adjustment for inhalability is turned
off.” (MPPD 2.11 Tutorial 1: Monodisperse for Rat,
http://www.ara.com/products/mppd.htm). We surmise
that the default option of the program was used in
Pauluhn [14] although use of the “inhalability correc-
tion” has been recommended by Oller and Oberdörster
[18] and it is listed by the MAK Commission as the op-
tion to choose ([11], p. 58). Again, input data and results
published by the MAK Commission in [11] are confus-
ing and the program version applied is outdated. The
entry “Check” for inhalability adjustment instead of
“Yes” or “No” on page 78 in [11] adds to this confusion.Model B: Sensitivity analysis: Outcome on the HEC estimate
Table 4 presents the following conclusions on derived
human equivalent concentrations. A higher HEC of
1 mg/m3 is estimated if we apply the alveolar deposition
fractions based on the MMPD input parameters as listed
by the MAK Commission [11] and Oller and Oberdör-
ster [18] (calculated with MPPD Version 2.0 or MPPD
Version 2.11). We obtain a HEC estimate of about
1.5 mg/m3 when using the alveolar clearance half time
in humans of 250 days as suggested by Gregoratto et al.
[32]. If the overload threshold (critical steady state par-
ticle volume burden) is modified from 1 μl/kg-rat to
4.2 μl/kg-rat, all estimates are increased by an additional
factor of 4.2. Thus, according to our calculations, the es-
timated HECs range from 1 mg/m3 to 7 mg/m3. Even if
the alveolar clearance half time of 400 days is used, as
proposed in Pauluhn [14] and by the MAK [11], the best
HEC estimate is 4 mg/m3 for a substance with a density of
1 g/cm3, which is considerably higher than the 0.5 mg/m3
value derived in [14] and [11]. Because of these rather high
HEC values and the large variation of almost an order of
magnitude, the Model B approach appears to be of little
value in general respirable dust OEL assessments.
Commentary on the models
We discovered that the metrics of Models A and B are
of dubious validity because of conflicting data. To pro-
vide another perspective on translating animal results to
humans, we examine the plausibility of the metrics
chosen, key epidemiological studies among worker co-
horts exposed to GBS and human studies in which
(bronchoalveolar lavage, BAL) results are available. We
note that Model A’s focus on alveolar surface area can
be criticized as it relies on a mode of action that is pre-
dominantly related to acute effects whereas, the main
interest is in the chronic effects of GBS exposure medi-
ated by macrophages [42].
The particle mass and volume metrics in comparison to
the particle surface area metric
The justification for the particle volume based approach
used in MAK’s Model B given in Pauluhn [14] refers to
Pauluhn [38] where is it is stated that “the key metric of
dose is particle mass and not particle surface area” [38].
Pauluhn [38] studied ALOOH (aluminum oxyhydroxides =
boehmite with primary particle diameters of 10 nm or
40 nm) and Fe3O4 (pigment-grade iron oxide =magnetite)
in Wistar rats. We note that the retained particle mass is
used as the numerator in the effect metric of MAK's Model
A but not in Model B which is the model recommended in
Pauluhn [14].
The author demonstrated (Figures Six, Seven and
Eight in [38]) that markers for pulmonary effects in the
lungs (e.g., polymorphonuclear leukocytes (PMN) cell
Morfeld et al. Particle and Fibre Toxicology  (2015) 12:3 Page 14 of 34counts) correlated well with retained particle burdens
expressed as mass but poorly when the exposure was
expressed in terms of particle surface area. Although evi-
dence was provided for the particle mass metric, the au-
thor did not dismiss the importance of the particle
volume based metric. “However, due to the difficulty to
reliably estimate PM volumes from aggregated PMs with
different densities, polydisperse particle sizes, and void-
spaces of packed particles within macrophages, volumet-
ric estimates, although considered to be mechanistically
important … were not considered in this analysis” [38].
This issue is complicated further as the surface area using
the BET (Brunauer, Emmett, and Teller) methodology per
se [43] is not necessarily a unique characteristic of a
particle. For instance, the specific surface area (N2 used as
adsorbent) of AlOOH-40 nm, after drying and degassing
(100°C at 0.1 mbar for 16 h) was 46.3 m2/g while under
other conditions of measurement (550°C for 3 h) the BET
was reported to be 105 m2/g. In Pauluhn [38] the larger
value was applied for analyses. It would have been of inter-
est to see how sensitive the reported findings are to the
different BET measurement values. The validity of both
approaches, Model A’s particle mass metric and Model B’s
particle volume metric, appears in doubt based on a study
of Tran et al. [44]. Male Wistar rats were exposed to aero-
sols of TiO2 and BaSO4 each at two separate concentra-
tions: 25 and 50 mg/m3 for TiO2, and 37.5 and 75 mg/m
3
for BaSO4. Duration of exposures were set to 209 days,
118 days, and 203 days and 119 days, respectively. The
mass burdens of TiO2 and of BaSO4 were determined in
lung and lymph-node tissue ([8], p. 1091–1093) and “lung
mass burdens were reexpressed in terms of total surface
area of deposited particles. The specific surface areas of the
two dusts were measured using Brunauer Emmett Teller
(BET) gas adsorption at Morgan Materials Technology
(Stourport-on-Severn, UK) from a sample of approximately
5 g of each dust” ([43], p. 116). Tran et al. [44] reported
that BaSO4 and TiO2 particles, of similar substance dens-
ity (BaSO4: 4.5 g/cm
3, TiO2: 4.25 g/cm
3), showed different
inflammatory responses across the retained particle mass
and retained particle volume scale but had similar re-
sponses on the retained particle surface area scale. The
authors concluded on p. 1117: “The results presented here
show that the total surface area of particles in the lung
may be the dominant measure when quantifying the tox-
icity of poorly soluble “nuisance” or PNOC [particulates
(insoluble) not otherwise classified] dusts. The strength of
the evidence lies in the consistency of the relationships be-
tween both PMN and lymph-node burdens, measured on
independent sets of rat lungs, and total surface-area bur-
den.” These relevant findings on the role of particle surface
area were not discussed in [14,38]. We further note that
Monteiller et al. [45] was cited in [38] as support of the
particle volume based approach–but this interpretationdiverges from the views of Monteiller et al. [45]. In their
discussion of low-solubility low-toxicity particles (LSLTP)
they wrote: “These in vitro data support the contention
that … surface area is the dose metric that relates best to
the inflammatory response for a range of LSLTP. This find-
ing accords with our previous in vivo studies, in which sur-
face area of LSLTP was found to be the factor driving the
inflammatory response in rats” ([45], p. 614]). This UK
working group came to the same conclusion in a review
on appropriate dose metrics for poorly soluble dusts [46].
Other authors concur with this finding [47,48].
Oberdörster et al. [49] presented strong evidence in
favor of the retained particle surface area concept and
evidence against the retained particle mass and retained
particle volume concepts by comparing nanostructured
and pigmentary TiO2 in a 12-week inhalation exposure
study in rats. The concentrations were 23.5 ± 2.9 mg/m3
for the nanostructured material and 22.3 ± 4.2 mg/m3
for the pigmentary TiO2. Upon aerosolization, both
TiO2 particle types formed agglomerates with mass me-
dian aerodynamic diameters of 0.71 μm (nanostructured)
and 0.78 μm (pigmentary) and with geometric standard
deviations of 1.9 and 1.7, respectively. Since the aero-
dynamic diameters of the aerosols were essentially the
same for the two particle types, the compartmental de-
position in the respiratory tract of the animals was ex-
pected to be very similar. The authors concluded on p.
177: “Neither average gravimetric nor average volumetric
burdens of both particle types correlate well with the ob-
served effect on AM clearance function. Expressing these
doses as the retained particle surface area in the macro-
phages shows that the effects on AM-mediated clearance
function of the two different particle types can be
expressed by a common dose–response curve”. Bermudez
et al. [50,51] confirmed these findings. Lison et al. [52]
concluded that, when conducting studies to elucidate
the effect of particles on the lung, it is important for insol-
uble particles such as manganese dioxide to consider the
administered dose in terms of surface area (e.g. m2/kg) ra-
ther than in gravimetric terms (e.g. mg/kg). ECETOC [34]
summarized arguments in favour of particle surface area as
the driving metric (Section 2.1.3, p. 10 and 11). Kuempel
et al. [53] judged that the appropriate metric to evaluate ef-
fects of poorly soluble, low-toxicity particles is surface area
dose of respirable particles. Cherrie et al. [9] suggested that
the ideal OEL would be based on surface area of dust per
unit volume of air inhaled “(e.g. cm2/m3)”. Saber et al. [54]
described in their Figure Five the appropriate effect metric
as a non-linear association between particle surface area
and neutrophil influx (PMNs) showing a NOAEC. John-
ston et al. [55] reviewed the particle attributes and bio-
logical mechanisms responsible for the observed toxicity
in vivo and in vitro studies of silver and gold particulates.
They concluded that differences in toxicology of smaller
Morfeld et al. Particle and Fibre Toxicology  (2015) 12:3 Page 15 of 34and larger particles are likely to be driven by differences in
particle surface area, when administered at an equal-mass
dose. Hext et al. [56] reviewed animal studies performed
with TiO2 and concluded that the observed responses were
consistent with the particle surface area of the lung burden.
Braakhuis et al. [57] reviewed and analyzed published data
on inhalation of nanoparticles to identify and evaluate
physicochemical characteristics of nanoparticles that affect
the development of pulmonary inflammation. Nanomater-
ials differ in their capacity to induce lung inflammation; no
unifying dose metric could be identified to describe pul-
monary inflammation for all nanomaterials. Surface
reactivity appeared to have the best correlation with pul-
monary inflammation. Simko et al. [58] proposed as dose
metric “the total deposited NP [nano particles] surface area
(SA), which has been shown frequently to determine toxico-
logical responses e.g. of lung tissue”. Further applications
and discussions arguing in favour of the retained particle
surface area concept are given in Duffin et al. [59] and
Donaldson et al. [60]. Maynard and Kuempel [61] per-
formed an overview and concluded from their Figure
Three that “despite the varying particle compositions, sizes
and morphologies, the aerosol surface area dose–response
relationship appears to be remarkably similar for poorly
soluble, low toxicity (PSLT) particles”.
In contrast to these researchers, the particle volume
approach is favoured in [42] as outlined in [14]. Al-
though the work of Tran et al. [44] is cited in these pub-
lications, the importance of their findings are not
discussed. The relevant study of Oberdörster et al. [49]
was not described in Pauluhn [42], which is unfortunate
because both studies [44,49] fulfill the conditions of in-
formative experimental studies adopted by the author.
We like to emphasize that Figure Eleven in [14] con-
firmed the problems Oberdörster et al. [49] had identi-
fied with the volume metric. All data points showing
results for non-nanostructured materials with lower par-
ticle surface area are below the curve in Figure Eleven,
and all data points for nanostructured materials with
higher surface area are above the curve (only exception:
Boehmite, ALOOH). Thus, there is no common re-
sponse curve of the alveolar clearance rate of low and
high surface area dusts across the volumetric dose as
shown before by Oberdörster et al. [49]. A recent review
[62] seemed to misinterpret the carbon black study by
Elder et al. [63] as some evidence in favor of the volu-
metric approach. We note that such a view contrasts
with the authors’ interpretation who stated in the ab-
stract that “the results from rats also show that particle
surface area is an important determinant of target tissue
dose and, therefore, effects”. In this sub-chronic rat study
with 13 weeks exposure time, the authors applied Prin-
tex 90, a high surface area carbon black, at 1 mg/m3,
7 mg/m3, and 50 mg/m3. In addition, they performed a13 week rat experiment with Sterling V, a low surface
area carbon black, at 50 mg/m3. First, according to the
design of Elder et al. [63] a concentration of 7 mg/m3
Printex 90 should produce about the same surface area
concentration as 50 mg/m3 of Sterling V. The authors
found that Printex 90, 7 mg/m3 showed less relative and
absolute PMN cell numbers than Sterling V. Second, if a
particle mass based metric were correct we expect to see
similar results when applying Printex 90 and Sterling V
at the same concentration of 50 mg/m3. Given an identi-
cal density of Printex 90 and Sterling V we also expect
similar results based on the particle volume model. We
note that Printex 90 (50 mg/m3) showed more pro-
nounced reactions, in particular when comparing abso-
lute PMN cell numbers and when evaluating PMN
findings after the longest post-exposure recovery time
period of 11 months. Given these findings we agree with
Elder et al. [63] who stated that the effect of Sterling V
was often between the effects of Printex 90 (7 mg/m3)
and of Printex 90 (50 mg/m3). The authors speculated
that other surface properties of Sterling V may have
amplified the effect of this low surface area carbon black,
particularly they mentioned the higher PAH (polycyclic
aromatic hydrocarbon) content of Sterling V. According
to Table One in [64] the PAH contents are 8.8 mg/kg
(Sterling V) and 0.039 mg/kg (Printex 90). Elder et al.
[63] seemed to conclude that surface area plays an im-
portant role because Printex 90 (50 mg/m3) showed
more pronounced responses than Sterling V (50 mg/m3)
despite the 225 times higher PAH content of Sterling V.
We emphasize that the low-surface area carbon black
(Sterling V) was only applied in one single concentration
in this inhalation rat study and that this concentration
was very high (50 mg/m3). Thus, other mechanisms may
be at work at such a high dosage because “results of key
studies reported for chronic inhalation of PSP [poorly
soluble particles] in rats indicate that mechanisms of
PSP-induced lung tumors at high doses do not operate at
low dose levels” [65]. Consistent with these results, a
significant increase (P < 0.05) in 8-oxoGua (8-oxo-7,8-
dihydro-2′-deoxiguanosine) induction was observed fol-
lowing 13 weeks of exposure to 50 mg/m3 Printex 90
and at 7 and 50 mg/m3 after the 44-week recovery
period [66]. Interestingly, no increase in 8-oxoGua was ob-
served for Sterling V at either time point. Although the
retained mass dose of Sterling V at the end of exposure was
even higher than for Printex 90 (50 mg/m3) (approximately
7.6 vs 4.8 mg), the surface area of the retained Sterling V
was similar to that of the retained Printex 90 of the mid-
dose exposure (7 mg/m3) (approximately 0.2 m2 in both
groups). Sterling V (50 mg/m3) and Printex 90 (7 mg/m3)
did not induce significant increases in 8-oxoGua in the lung
at the end of the 13-week exposure. Gallagher et al. [66]
noted that “the lower effect per unit mass dose seen with
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particle surface area of low toxicity particles is a more ap-
propriate dose metric for induction of inflammation in the
lungs”. We conclude that the observations in Elder et al.
[63] are no reliable evidence against the importance of the
surface area metric.
Finally, Tran et al. [67] developed an approach to esti-
mate the no-observed adverse-effect levels in rats taking
multiple lung compartments into account and using par-
ticle surface area as the relevant dose metric. They ap-
plied this approach to the data from Tran et al. [44].
This study derived a NOAEC of 3.5 mg/m3 for TiO2 and
7.5 mg/m3 for BaSO4, varying with different particle sur-
face areas of the substances. In contrast to these find-
ings, using a particle volume or particle mass based
approach would return almost identical NOAECs for
both substances.
As a side note, the corrected NOAEC estimate-based on
the particle volume metric - was calculated at 7 mg/m3 for
a substance density of 1 g/cm3 (see Table 4) which is in
the range of the findings in Tran et al. [67]. Tran et al.
[67] incorporated an additional “safety factor” of about 5
to address inter-animal variability (see Figure Seven in
[67]) that almost compensates for the higher density of
4.25 g/cm3 (TiO2) and 4.5 g/cm
3 (BaSO4). This crude coin-
cidence in numbers should not be misinterpreted as a justi-
fication of the approach. Reliable translational toxicology
models are difficult to develop and are too often believed to
be reliable although having no validation [2,68].
The low toxicity of BaSO4 was also emphasized by Klein
et al. [49]. Landsiedel et al. [53] reported on an inhalation
study on rats exposed to 13 metal oxide nanomaterials
and micron-scale zinc oxide for five consecutive days with
14- or 21-day post-exposure observation with concentra-
tions ranging from 0.5 to 50 mg/m3. Bronchoalveolar lav-
age fluid (BALF) and histopathological sections of the
entire respiratory tract were examined. Nano-BaSO4 did
not induce any treatment-related effects up to an aero-
sol concentration of 50 mg/m3. These results are con-
sistent with a previous study investigating BaSO4
effects upon intratracheal instillation [54], where bolus
doses of 4.8 mg per rat lung did not affect any parame-
ters of the BALF.
In summary, based on our review, retained surface
area appears to be a reliable unifying denominator to as-
sess pulmonary toxicity due to exposure to GBS. The
most critical question to consider in using translational
toxicology with any particulate substance however, is de-
ciding on which of the many physico-chemical proper-
ties it may possess are most relevant (see Table Three in
[69]). Thus, the weight of evidence indicates that no one
metric can be applied to all GBS substances. In particu-
lar the findings with BaSO4, a GBS, challenge the basic
assumptions of MAK’s translational toxicology models.A recent report from ECHA outlining the best practices
for human health and environmental risk characterization
of nanomaterials came to very similar conclusion (see
Section 3.2.1 in [70]). Thus, the approach of the MAK
Commission which dismisses the particle surface area
metric and does not test which metric is more appropriate
under various circumstances appears unconvincing [11].
A search for the most appropriate effect metric (single
or in combination) may be performed by multivariable
statistical procedures successfully used in meta analyses.
Unfortunately, these statistical tools are rarely used in
toxicology although they can help to overcome draw-
backs of elementary and univariable approaches applied
currently [71-75].
Epidemiology of GBS and related dusts
Coalmine dust: No lung overload and no lung cancer excess
risk in workers
In an attempt to provide a perspective on risks of lung
cancer under conditions of “lung overload”, we chose to
review mortality studies of coal worker and other dust-
related industry cohorts. Exposure to coal mine dust
particulates in miners has long been recognized as one
distinct occupation with significant potential for expos-
ure to dusts, especially in past decades. It can be in-
structive to address the results of these studies in
considering the potential human significance of high
dose rat inhalation studies. Particle overload is typified
by an impairment in alveolar particle clearance ([34],
p. 1 and 4).
Intensive investigations in the US and in the UK
showed that coalminers did not develop overload - even
under high exposure conditions [33,76]. Kuempel et al.
[33] studied pathologic data of 131 US coal miners
(mean age at death: 67 years, average cumulative dust
exposure: 107 mg-year/m3, 36 years of exposure, mean
coal mine dust concentration: 3 mg/m3). The mean lung
dust burden was 13.8 g (sd = 8 g) while the mean lymph
dust burden, among the subset for which lymph data
were available, was 1.6 g (sd = 1.6 g).
Tran and Buchanan [76] analyzed the pathological
data of 423 UK miners: mean age at death: 67 years,
average cumulative dust exposure: 256 gh/m3 = 145 mg-
year/m3 (assuming 220 working days per year with a
shift length of 8 h). The mean lung dust burden was
14.4 g (sd = 11.7 g) while the mean lymph dust burden,
among the subset for which lymph data were available,
was 2.3 g (sd = 1.0 g).
Kuempel et al. [33] referred to a dosimetric model devel-
oped in 1997 (PhD thesis of Eileen Kuempel) and found
that a three-compartment model with no clearance break-
down fitted the lung burden best when analyzing the aut-
opsy data of the US coalminers. Tran and Buchanan [76]
tested this hypothesis in their independent and larger set
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was achieved when the alveolar clearance rate was set in-
variant, i.e., the two independent studies present convin-
cing evidence that even under the historically-high dust
exposure scenarios of coalminers, no lung overload oc-
curred in humans [33,76]. This result and the related
Gregoratto model [32] were confirmed once more in a
more recent study using both data sets in a Bayesian ana-
lysis via Markov Chain Monte Carlo simulations [77].
Coalminers do not suffer from elevated lung cancer
risks [78,79]. In the most recent study on US coalminers
[80] the lung cancer standardized mortality ratio (SMR)
was only slightly elevated (SMR = 1.08, 95% CI: 1.00-
1.18). This excess is unexceptionable because of the
higher proportion of smokers at the start of the study in
1969/1970 (current smokers: 54%, Supplement Table
Four in comparison to the US male population in 1970
(current smokers: 44.1%). Internal analyses showed an
association of lung cancer mortality with coalmine dust
exposure but only during the last follow-up interval
from 2000 to 2007. All follow-up periods until 2000
showed no association between coal mine dust exposure
and lung cancer [80,81]. The study relies on smoking in-
formation collected only at the start of follow-up. The
models are unable to adjust for smoking habits after
leaving work. Note that current smokers smoked less
when working as a coalminer than current smokers in
the US male population (prevalence of smoking more
than 25 cigarettes per day: 12.4% among US coalminers
vs. 28.0% in the US male population). This difference is
probably caused by prohibition of smoking when work-
ing underground. It is plausible that smoking coalminers
have increased their intensity of smoking after cessation
of work underground and that this may have caused an
increase in lung cancer mortality during the last follow-
up period when most coalminers of the cohort have
already stopped working underground (see the discus-
sion of this issue in [82]). The US study [80] has an in-
complete assessment of jobs held; no start and end date
of jobs/tasks held before 1969/1971; no information on
jobs/tasks held after start of follow-up in 1979/1971 and
no end date of working as a coalminer for 16% of cohort
members. Thus, only a crude assessment of exposure to
coalmine dust up to the start of follow-up was possible:
no time-dependent exposure analysis or lagging or lug-
ging of exposures could be done. Crystalline silica
concentration data suffered from additional limitations
because measurements were available only after 1982
but had to be allocated to the jobs held before 1969/
1971. Shortcomings and errors of this study were dis-
cussed in two Letters to the Editor [83,84]. The largest
study to date with better assessment of exposures in a
time-dependent manner was performed in the UK [82]:
the overall evidence does not support an excess in lungcancer risk among coal miners, when compared to the
general population or in internal analyses of the effect of
coal mine dust exposure [85]. Similar results were found
in Germany, based on a detailed and time-dependent ex-
posure assessment in an analysis of lung cancer mortal-
ity and incidence data [79,86-88].
A study on US coalminer counties indicated cancer
excess risks [89]. This study may be severely biased due
to the ecological fallacy [90].
We would like to emphasize that all coalminer mortal-
ity studies discussed in this Section showed a link be-
tween coal mine dust exposure and coal worker’s
pneumoconiosis, a clear sign of substantial dust expos-
ure and tissue reaction. Thus, even in the presence of
pulmonary fibrosis, no increase in lung cancer was re-
ported in relation to coal mine dust.
Titanium dioxide, toner and carbon black: No lung cancer
excess risk in workers
As with coal miners, no lung cancer excess risks were
found in large cohorts of toner and TiO2-exposed
workers as to be described below. A multi-center occu-
pational epidemiology study was performed in Europe
that enrolled 15,017 workers long-term exposed to TiO2
[91]. Four US production plants with a total of 4,241 ex-
posed workers were studied [92]. An epidemiological in-
vestigation was performed on 33,671 workers with
exposure to toner [93]. None found a lung cancer excess
risk due to dust exposure. No evidence of adverse effects
on pulmonary function indices and chest x-rays and no
evidence of excessive inflammatory, allergic, or oxidative
stress reaction was present in the toner-handling
workers as compared to the nonspecifically exposed
workers (1504 male workers in a Japanese toner and
photocopier manufacturing company, means of personal
8 h respirable dust concentrations spanned from
0.012 mg/m3 in toner manufacturing to 0.989 mg/m3 in
toner and photocopier recycling) [94-96]. The oxidative
stress reaction was determined by urinary 8-oxoGua, a
sensitive biomarker for increased repair of oxidatively
damaged DNA. This biomarker has been successfully
used in studies on environmental and occupational par-
ticle exposures (e.g., [97,98]). A Working Group at the
International Agency of Research on Cancer (IARC)
concluded that the evidence in humans for the carcino-
genicity of TiO2 was inadequate [99,100].
Kuempel et al. [101] commented on a comparison of
rat-based risk estimates (MLE, maximum likelihood esti-
mates) by translational toxicology and epidemiological
risk assessments: “Regarding the magnitude of the excess
risk estimates, the rat-based MLEs were clearly higher
than the human-based estimate for coal dust (which was
negative); however, the rat-based estimates (MLEs and
95% UCLs) did not exceed the 95% UCL from the
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based excess risk estimates exceeded those from the hu-
man study, but the differences were not statistically
significant. For titanium dioxide, the rat-based excess
risk estimates (MLE and 95% UCL) were lower than the
95% UCL of the human studies, although the MLE from
Fryzek et al. [10] was negative”. These results of Kuempel
et al. [101] showed that the rat findings are difficult to
rely on when the toxicological effects of GBS dust in
humans are to be estimated in quantitative terms. For
coal mine dust and carbon black these authors found
that the rat estimates are in excess in comparison to the
humans. Because of statistical imprecision such a state-
ment could not be derived for TiO2 but the authors
stated that the epidemiological findings on TiO2 were
negative.
The mortality of carbon black (CB) production workers
has been extensively studied in the USA and in Europe
[102-110]. Three major cohort epidemiological studies
were performed in the UK, USA and Germany to investi-
gate lung cancer mortality in CB production plants.
A UK cohort study on 1,147 workers at five plants
[108] found a SMR of 1.73 (61 cases, 95% CI: 1.32 -
2.22). No trend across crudely assessed cumulative ex-
posure, lagged up to 20 years was noted. Elevated lung
cancer SMRs were observed at two plants: the SMRs of
the other three plants were unexceptionable.
A German study of 1,528 workers at one plant
[103,104,110,111] estimated an SMR = 1.83 (50 cases,
95%-CI: 1.34 - 2.39) but there was no link with CB expo-
sures. However, the German study identified smoking
and prior exposures to known carcinogens as important
risk factors that could explain the major part of the ex-
cess risk [104]. A US cohort study on 5,011 workers at
18 plants [102] calculated an SMR = 0.85 (127 cases,
0.95-CI: 0.71, 1.00) and found no trend across time since
first exposure and duration of exposure in years.
A Working Group at IARC concluded that the evidence
in humans for the carcinogenicity of CB was inadequate
[99,100]. An overview of these studies is described in
McCunney et al. [112]: no lung cancer excess risk among
CB workers could be established. This view is supported
by studies in the CB user industries [113,114].
Since this IARC [100] evaluation, in an extended
follow-up of the UK study, Sorahan and Harrington
[109] applied a novel exposure metric (“lugging”) while
hypothesizing that CB may act as a late stage lung car-
cinogen at plants with elevated SMRs. If so, the elevated
SMRs of lung cancer should decrease substantially after
cessation of exposure and positive associations should
be found with “lugged” cumulative CB exposure (“lug-
ging” the exposure by 15 years means to count only ex-
posures received during the last 15 years). Sorahan and
Harrington [109] observed both phenomena in those(and only those) two UK plant cohorts that had elevated
lung cancer SMRs. The authors suggested that other in-
vestigators attempt to reproduce their findings. Morfeld
and McCunney [105] tested this hypothesis in the
German CB cohort. No decreasing SMR after cessation
of exposure was observed, despite the fact that the
German cohort showed an elevated lung cancer SMR.
Further analysis of the German CB cohort addressed
potential “lugging” effects with a multi-model Cox re-
gression approach [106]. This effort was designed pri-
marily to explore the impact of cumulative exposure to
CB “lugged” at 5, 10, 15, and 20 year - in other words, to
evaluate the risk of lung cancer based on exposures
within the most recent 5, 10, 15, and 20 years of expos-
ure. Four cohorts within the overall cohort were evalu-
ated including an inception cohort with different
exposure scenarios. Despite extensive searching, 719
models returned negative coefficients. Only one model
estimated a small positive, nonsignificant coefficient.
This analysis did not support the hypothesis of CB being
a late-stage carcinogen [109].
Bayesian analyses were also employed [107] to explore
potential risk factors and confounders that may have
contributed to the SMR lung cancer results. When put-
ting a flat prior to the SMR a Markov chain of length
1,000,000 returned a median posterior SMR estimate
(that is, the adjusted SMR) in the range between 1.32
(95% posterior interval: 0.7, 2.1) and 1.00 (0.2, 3.3) de-
pending on the method of assessing previous exposures.
These additional studies provide further support for the
lack of an increased risk of lung cancer as a result of
working in the CB – producing industry.
A US cohort study on 5,011 workers at 18 CB – pro-
ducing plants [102] calculated an SMR for lung cancer
of 0.85 (127 cases, 0.95 CI: 0.71, 1.00) and found no
trend across time since first exposure and duration of
exposure. No estimates of exposure intensities or cumu-
lative exposures were available for this cohort.
The relationship between workplace exposure to CB and
lung cancer risk was examined in two large population-
based case–control studies carried out in Montreal,
Canada Study I: [113], Study II: [114]. Interviews for Study
I were conducted in 1979–1986 (857 cases, 533 population
controls, 1,349 cancer controls) and interviews for Study II
were conducted in 1996–2001 (1,236 cases and 1,512
controls). Detailed lifetime job histories were elicited
and a team of hygienists and chemists evaluated the
evidence of exposure to a host of occupational sub-
stances, including CB. Lung cancer risk was analyzed
in relation to each exposure, adjusting for several po-
tential confounders, including smoking. Subjects with
occupational exposure to CB, TiO2, industrial talc and
cosmetic talc did not experience any detectable excess
risk of lung cancer.
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well-investigated respirable GBS (including some nano-
structured dusts) such as coal mine dust, TiO2, toner or
CB and no excess in lung cancer risk in humans has
been demonstrated.
BAL studies in humans are consistent with
epidemiological results
As discussed before, epidemiological data do not provide
convincing support for an increased lung cancer risk in
people exposed to high dust levels, such as coal miners.
Epidemiological findings contrast with the results of ex-
perimental studies on rats, in which at higher exposure
levels, excess lung tumours were detected. Chronic in-
flammation is the underlying mechanism, which causes
secondary genotoxic events by oxidative damage due to
inflammatory cells. Consequently, prevention of inflam-
mation is the rationale for the establishment of threshold
values (MAK values) by the MAK Commission [11]. The
experimental studies were evaluated mainly by analyses
of inflammatory cells (PMNs) in the BALF (e.g. [14]).
Thus the BALF-PMN in the rat experimentation oper-
ates in a dual way: (a) the “causative (true)” biomarker
for the prevention goal and (b) the parameter for the as-
sessment of the NOAEL and the derived setting of MAK
values.
BAL is a widely used clinical diagnostic study in the
evaluation of lung disorders, particularly in the differen-
tiation of interstitial lung diseases (ILD). In light of the
emphasis given by the MAK Commission to data from
rat experiments, it would be valuable to determine
whether corresponding biomarkers can be identified in
human BALFs of dust-exposed people. BALFs on coal
workers were assessed for their cellular profile [115-119].
Groups of miners with different stages of coalworkers’
pneumoconiosis (CWP) were compared (posterior-anter-
ior chest radiographs, ILO resp. Chinese x-ray staging of
CWP). No increased counts for PMNs were detected in
asymptomatic miners [115-117] and in miners with
low grades of simple pneumoconiosis, i.e., CWP ≤ 1/1
[115,116]. One group of miners with simple pneumoconi-
osis showed an elevation of the neutrophil percentages in
the BALF in comparison to controls [118]. In contrast, a
second group studied by the same researchers showed al-
most the same average neutrophil percentage as reported
for controls [119]. Unfortunately, the distribution of CWP
degrees was not given in these studies and the potential
overlap of both investigations is unclear. We note that the
recovery techniques may have differed between research
groups and the frequency of neutrophils were reported on
varying scales (percentages, counts per ml).
Xing et al. studied biomarkers in the BALFs of coal
mine workers: 14 active underground miners without
CWP, 21 workers with CWP 0/1, and 13 no longerexposed workers after cessation of exposure with CWP
1/1. None of the groups showed elevated neutrophils
numbers (PMNs). However, other biomarkers in the
BALF of the coal workers were clearly changed; for in-
stance markers of the epithelial reaction (pneumocyte
type II): (a) increased surfactant lipids, (b) altered ratio
of PG/PI (subgroups of lung surfactant: phosphatidylgly-
cerol PG, phosphatidylinitisol PI), (c) increased surfac-
tant protein A. The elevated TNF alpha content in the
BALF (d) stands for the effect of the phagocytosed parti-
cles on AM. Interestingly, the results on parameters
(a, b, d) correspond to findings in dust-exposed rats, e.g.,
the increased surfactant lipids, the altered ratio of PG/
PI, the elevation of TNF alpha [120-123]. It is worth
mentioning that rats exposed to coal dust showed a sig-
nificant increase of PMNs in the BALF, e.g. [124]. The
investigations of Vanhee et al. [125] identified different
profiles of growth factors (PDGF, IGF1, TGF beta) in the
BALF of coal miners according to the severity of x-ray
changes. Further in vitro and in vivo studies on human
(BALF-) alveolar macrophages from patients with differ-
ent grades of pneumoconiosis clearly demonstrated the
eminent role of the AM for the onset and development
of the coal miners’ lung disease [119]. Mixed CS and
coal dust exposures eventually trigger an aggressive form
of pneumoconiosis and BALF pattern [117]. The miners’
individual working-lifetime exposures (n = 20) were esti-
mated from this study, using work histories and airborne
mine dust data. The quartz lung-burdens were calcu-
lated using a lung dosimetry model. The study showed
that quartz, either as cumulative exposure or as calcu-
lated lung burden, was a highly significant predictor of
PMN lung response. The cumulative coal dust exposure
did not contribute to the prediction of PMNs [126].
An ATS clinical practice guideline on the utility of
BALF cellular analysis [127] summarized for CWP that
BALF cell profiles, indicative of increased numbers of
macrophages and elevated proportion of coal dust-laden
macrophages, are suggestive of CWP or progressive
massive fibrosis (PMF). The authors stated for silicosis
that BALF profiles of silica-exposed workers and
workers with silicosis are characterized by an excess in
BALF macrophages and an increased silica particle bur-
den of macrophages that is appreciable in non-smokers.
Meyer et al. [127] made no recommendations regarding
the clinical utility for prognosis of CWP or PMF. The
authors noted about the prognostic value for silicosis
that increased numbers of lymphocytes and neutrophils
have been associated with progression to silicosis.
In conclusion, the prominent role given to the BALF-
PMNs in relation to the particle lung exposure in rats does
not correspond to BAL results in humans. Human data re-
flect a significant role for the alveolar macrophages [128]
and type II pneumocytes in the development of dust
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The PMNs, however, play a unique role in rat experi-
ments, findings that do not appear to occur in high dust
exposed workers, such as coal miners. In conclusion, the
human BAL biomarker studies corroborate the epidemio-
logical findings described in the earlier Section.
Comparative interspecies responses to GBS exposure
Species-specific response to GBS in inhalation studies
Although the rat has been the experimental species most
extensively used in GBS investigations and there is thus,
an abundance of pathophysiological and toxicokinetic
data for a range of GBS, it is important to consider how
relevant all this information is when reading across,
using translational toxicology to other species and in
particular, humans. In a Letter to the Editor Kuempel
et al. [10] noted that there are similarities between the
human lung responses to respirable particles compared
to those observed in rats exposed to overload doses. The
authors stated that an “ILSI expert panel concluded that
the rat is a useful model for non-neoplastic lung re-
sponses to poorly-soluble particles and that (in the ab-
sence of mechanistic data to the contrary) it is also
relevant to identifying potential carcinogenic hazards in
humans.” This contrasts somewhat with a description of
the ILSI panel [129] given on page 4 in [34]:
“The main conclusions from this ILSI workshop on
‘lung overload’ can be summarised as follows:
 Hallmark of particle overload is impaired alveolar
clearance.
 Precise mechanisms are not known but volumetric
inhibition of macrophages and the development of an
inflammatory environment seem to be important
drivers.
 Differences in potency of various PSPs are obvious
and are leading to the need of dosimetric
adjustments accounting for differences in deposition
and clearance of particles.
 Overload is not a rat specific phenomenon and seems
to be generally reversible but may reach conditions
where clearance impairment is irreversible.
 Overload contributes to the (species independent)
pathogenesis of non-neoplastic lung responses and is
a prerequisite for the tumorigenic effects observed in
rats. With regard to humans, despite evidence that
particle clearance is impaired in many coal workers,
no conclusive evidence for increased lung cancer risk
exist for workers chronically exposed to coal dust or
for workers exposed to other poorly soluble particles.
 For neoplastic lesions, dose–response data from
persistent neutrophilic inflammation and cell
proliferation can be used as surrogate for risk
characterization. For non-neoplastic responses, persistent neutrophilic
inflammation may also be used a surrogate whereas
epithelial cell proliferation is not considered a
necessary prerequisite for fibrosis.
 A nonlinear dose–response approach for the
characterization and evaluation of both, neoplastic
and non-neoplastic lesions are considered plausible
based on the assumed pathogenesis.
 An uncertainty factor of 1 for both neoplastic and
non-neoplastic endpoints can be considered sufficient
to account for toxicokinetic and toxicodynamic
parameters.
 With regard to an appropriate dose metric some
estimate/parameter reflecting retained lung burden is
recommended together with a full characterization of
the aerosol exposure parameters (e.g. MMAD,
particle surface area, density).
 With regard to non-neoplastic responses the rat is
considered predictive of a non-neoplastic hazard for
humans.
 With regard to neoplastic responses the rat is
considered to be more responsive than other species
including humans at doses and exposure intervals
that result in pulmonary particle overload.
 The mode of action for induced neoplastic responses
in rats apparently needs accumulation of particles in
lung alveolar and interstitial compartments,
persistent inflammation and epithelial cell
proliferation”.
We thus note that there is a continuing debate regard-
ing the similarities (nature and extent) of the effects in
rats (and other experimental species) and humans. In
the following, we will review species differences again,
but focusing on the MAK Commission’s approach. In
the translational Model B used by the MAK Commis-
sion, much is predicated on the rat lung alveolar macro-
phage (AM) responses to GBS. However, it is well know
that there are important differences in species differ-
ences in composition, localization, and function between
the different AM subsets which may well account for
some of the observed differences in responses to inhaled
GBS.
As one example, this is demonstrated with the finding
that the shortest AM clearance times are reported for
rodents where deposited particles remain on the epithe-
lial surface of the lung [130,131] whereas, longer clear-
ance half times are found in humans, monkeys, dogs and
guinea pigs [132,133]. Species differences exist also in
the cell size of AMs, with those from humans being sig-
nificantly larger than those from rats, hamster or mon-
keys. These differences in size have been considered in the
AM pool volume model [14] and in Model B of the MAK
Commission [11]. In addition, it has been observed that
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vary among species [134].
To highlight this difference in AMs between species, it
is interesting to note that Dörger et al. [135] and Jesch
et al. [136] reported that nitric oxide formation was only
observed by rat AMs, but not in the AMs from ham-
sters, monkeys or humans. The authors concluded that
specific regulatory mechanisms of the nitric oxide path-
way in AMs from these four different species existed.
In spite of extensive research, it still remains unclear
why rats alone respond with the development of lung tu-
mours, but other animal species, chronically exposed to
GBS, do not. Clearly, the role of stimulated AMs and
PMNs is important as lung tumours have never been re-
ported in rats when pulmonary inflammation was absent
[129,137-140].
The greater sensitivity of the rat lung with regard to
oxidative stress and subsequent epithelial cell responses
is most likely due to a more pro-inflammatory environ-
ment compared to other experimental species. The con-
sistent finding that lung tumours in rats following
chronic exposure to GBS are induced by such an indir-
ect mechanism is supported by results of other experi-
ments. Inflammatory cells and activated AMs, which are
found in large numbers in animals exposed to GBS, can
release ROS and other mediators of inflammation, which
in turn, are able to induce DNA damage by a secondary
mechanism [138,141-143]. In contrast to this finding in
rats, no other animal species, including mice and ham-
sters have been reported to have developed lung tu-
mours following such chronic exposure to GBS.
Of particular importance for risk assessment is the ob-
servation that the pulmonary responses of rats are
extremely marked when compared to other large mam-
malian species such as non-human primates and
humans. It has been proposed that the intrapulmonary
particle retention patterns and tissue reactions in rats
may not be predictive of pulmonary retention patterns
and tissue responses in either primates or humans as re-
ported by Nikula and coworkers [144,145]. In these
studies, male monkeys and rats were exposed for
7 hours/day, 5 days/week for 24 months to diesel ex-
haust particulates (2 mg/m3), coal dust (2 mg/m3), or
diesel exhaust particulate and coal dust combined
(1 mg/m3 each) and were subsequently examined histo-
pathologically. In all the exposed groups, monkeys
retained a similar amount or more particulate material
in the lungs than did the comparative rats groups. Ex-
posed rats retained a greater fraction of the particulate
material in the alveolar ducts and alveoli, whereas mon-
keys retained a greater proportion of particulate material
in the interstitium. Most importantly, rats, but not the
monkeys, developed significant alveolar epithelial hyper-
plastic, inflammatory, and septal fibrotic responses tothe retained particles. It was proposed by the authors
that these differences in particulate tissue distribution in
rats and humans might bring different lung cells into
contact with retained particulates or particle-containing
macrophages. This may, in part, account for the differ-
ences in species responses to inhaled GBS.
The authors concluded: “These results suggest that
intrapulmonary particle retention patterns and tissue re-
actions in rats may not be predictive of retention patterns
and tissue responses in primates exposed to poorly sol-
uble particles at concentrations representing high occupa-
tional exposures. The pulmonary responses of the rats
were severe compared to the primate, where the insult to
the lungs was handled without adverse consequences”
[144].
Nikula et al. [35] also have demonstrated that the rela-
tive amounts of intraluminal and interstitial particle load
differ markedly between rats and humans with particles
being found predominantly in the interstitium in man
and intraluminarly in rats. This is consistent with the
finding that acute intra-alveolar inflammatory responses,
alveolar epithelial hyperplasia and alveolar lipoproteino-
sis were all significantly more pronounced in rats com-
pared to humans exposed to the same particles [146].
This further supports the author’s contention above that
these differences may also account for the species differ-
ences seen in the long-term responses to high GBS
exposures.
The IARC Working Group [147] noted that the dose
metric that best describes the dose–response relation-
ship for GBS with lung tumour induction in the rats can
be surface area, particle and size [148-150]. Interestingly,
they remark that the degree of sustained inflammation
experienced by rodents (most notably rats) at high lung
burdens has not been observed in humans. It is of par-
ticular relevance to note their following conclusion in
regards to interspecies responses to GBS.
“Rats and mice, in contrast to hamsters, exhibit sus-
tained inflammation associated with particle lung
burden, but lung tumours induced by poorly soluble
particles have only been observed in rats. It has been
shown that rats are uniquely susceptible to poorly sol-
uble particle-induced lung cancer relative to mice and
hamsters. While some of the steps indicated in Figure
4.2 have been demonstrated in humans exposed to
poorly soluble particles, it is not known to what extent
humans are susceptible to particle-induced lung can-
cers associated with titanium dioxide, carbon black or
talc” [147].
Another approach to considering the interspecies lung
reaction to GBS is the use of the “Adverse Outcome
Pathway” (AOP) approach. This model describes the se-
quential progression of events evolving in an organism
from the first contact of a toxicant at the molecular
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responses to a final adverse outcome at the individual or
population level [151]. Although AOPs can be outlined
as a linear cascade of consecutive events, where one
common molecular initiating effect is the prerequisite
for all subsequent steps, the “adverse outcome” may vary
significantly. In this respect, AOPs take into account that
different molecular initiating events can cause the same
adverse outcome as well as that many different “mode-of
actions” (MoA) share common key molecular initiating
events. Even though the adverse outcome observed
in vivo is the result of a sequential cascade of biological
events, each step in this pathway may itself be influ-
enced by other pathways ongoing and/or dominating
within the biological system of interest.
This AOP approach has been recently used to de-
scribe an interspecies comparison of response to high
exposures to GBS [34] in experimental rodent species
and humans. Although an accumulation of particles
in the lung is a common finding in all investiga-
ted species, significant differences in the phenotypic
“adverse outcome” between rats and all other mam-
malian species, including humans, exist. As noted
earlier, lung tumours have been reported exclusively
in rats, but not in mice, hamsters, non-human pri-
mates or humans. It is well established that lung
“overload” also contributes to the observed (species
independent) pathogenesis of non-neoplastic lung re-
sponses, with the significant impairment of pulmonary
particle clearance as “initial event” relevant for AOP
considerations.
The application of the AOP approach to a number of
chronic inhalation bioassays with a range of GBS and other
experimental data leads to a helpful summary of findings as
exemplified with Table 5 taken from ECETOC [34].
Species-specific response to GBS on the cellular and
molecular level
One can explore the AOP approach by examining toxi-
cological studies that have investigated species-specific
differences with regard to the species-specific responses
to GBS on the cellular and molecular level, a condition
which makes up a central hypothesis in the MAK Com-
missions’ GBS document [11]: Basic assumptions are
that secondary genotoxic mechanisms underpin particle
genotoxicity and tumourgenicity. In vitro and in vivo
toxicological studies have consistently demonstrated that
the tumour induction in lungs of rats by particles is
closely linked to inflammation and ROS released by ex-
cessively particle loaded alveolar macrophages and by
secondary elicited PMN [148,152,153]. The critical
events are listed in Table 6 below.
ROS is highly DNA reactive and leads to mutagenic
DNA modification such as 8-oxoGua [121,154].Normally, cells possess potent defense mechanisms lead-
ing to a steady state level of 8-oxoGua via antioxidants
systems as GSH and SOD. Inflammation evokes higher
amounts of ROS, eventually overloading the defense
mechanisms. However, adaptive responses compromise
higher expression of higher antioxidant molecules (front
line defense), which according to the experimental data
is also species specific (see Table 7). In proliferative com-
petent cells, a DNA damage check point arrests cell
cycle via cell autonomous responses to allow time for
any DNA damage to be repaired [155] leading to gen-
omic maintenance. In the case of a severely DNA dam-
aged cell, the DNA checkpoint advances tumour
suppressor mechanisms such as apoptosis or senescence.
Basically, the GBS - alveolar macrophage interaction
initiates a cascade of events, which eventually leads to
critical biomarkers of mutagenic oxidative DNA damage
(8-oxoGua) (see scheme in Table 6). To explore the
AOP approach, data from three studies were extracted:
A subchronic inhalation study with CB which compares
the key pro- and anti-inflammatory markers of rat, mice
and hamsters [156]. These markers were allocated to the
phase 1 and 2 levels of particle lung interaction (see
Table 6). The two other studies considered, take into ac-
count the lung reaction after crystalline silica (CS) ex-
posure of rat and hamsters.
CS has a high surface activity which stimulates inflam-
matory responses in the lungs of rodents. After CS par-
ticle exposure the rat model presents the same essential
cellular and molecular events (Table 6), which are rele-
vant for the GBS inflammatory potential at significant
higher doses [121]. This cascade of events following ex-
posure to CS particles includes [123]: ROS release from
AM, elicitation of inflammatory mediators, recruitment
of PMN, radical scavenging, mutagenicity, oxidative
DNA damage. Taken together, critical steps in the lead-
ing section of the AOP to tumour formation in the rat
model are identical after (high) GBS and (low) CS expos-
ure. Thus, an approach to compare the different steps
(see Table 7) in different species (rat, mouse hamster) in-
cluding data from CS studies sounds reasonable.
One acute study tested CS (Min-U-Sil) at two moder-
ate doses (0.2 and 2 mg) and one high dose (30 mg) via
intratracheal installation on rats and hamsters (160–
180 g BW) and a post exposure interval of 7 days [157].
Both species were studied for lung reactions via BALF cell
count (PMN), BALF cell oxidant and NO production and,
expression of pro-inflammatory and anti-inflammatory me-
diators. Both species responded to the CS challenge (ham-
ster essentially to the extreme dose, 30 mg). However rat
showed much higher reactions in this acute study than
hamster in all parameters investigated.
The second CS study analyzed the lung reactions of
rat and hamsters at two moderate doses of quartz
Table 5 Interspecies lung responses afollowing long-term or chronic inhalation exposure to GBS
Species
Rat Mouse Hamster Primate/human
Likelihood for developing particle
overload (slow lung clearance)
+++ +++ + Not determined*
Alveolar macrophage participation
Active (accumulation in alveolar ducts) Active (accumulation
in alveolar ducts)




+++ +++ + +
Epithelial and interstitial cell proliferation
+++ + (+) (+)
Septal fibrosis
+++ + (+) (+)
Anatomical location of retained particulates




Rapid clearance Primarily interstitial
Lung tumours following chronic exposure
Yes No No No
aSeverity low +, moderate ++, high +++, or questionable (+), reprinted with permission from ([34], p. 52)**.
*This should be + (see p. 53 in [34]) because particle overload is typified by an impairment in alveolar particle clearance (see p. 1 and 4 in [34]).













Table 6 Cascade of cellular and molecular biological events following particle lung exposure
Phases Hallmark
Phase 1 Production of inflammation
promoting mediators
● Stimulation of primary ROS from AM, RNS
● Stimulation of secondary ROS, RNS from
AM, PMN (epithelial cells)
● TNF alpha, MIP2 from AM
● PMN recruitement




● Anti-inflammatory cytokine IL-10
Phase 3 Repair of injury ● Stimulation of DNA-repair mechanisms
Phase 4 Intermediate endpoints ● 8-oxoGua
● Proliferation
Abbr.: 8-oxo-7,8-dihydro-2´-deoxiguanosine: 8-oxoGua, alveolar macrophages: AM, reactive oxygen species: ROS, reactive nitrogen species: RNS, glutathione: GSH, macrophage inflammatory protein 2: MIP 2,













Table 7 Comparison of initial cellular and molecular events after lung particle exposure in different experimental
animals leading to pre-tumour conditions: DNA damage, p53 activation and proliferation
Phase # Parameter Animals compared; model used comparison Source
Phase 1 PMN BALF; rat mouse hamster R >> >M, H Carter and Driscoll [156]
Carter et al. [157]
Phase 1 PMN BALF; rat, hamster R >> > H Seiler et al. [158]
Phase 1 MIP2, TNF alpha BALF AM; rat mouse, hamster R >> > H, M Carter and Driscoll [156]
Carter et al. [157]
Phase 2 IL-10 Rat, mouse hamster R, M < << H Carter et al. [157]
Phase 2 GSH level in BALF Rat vs. hamster R >> > H Seiler et al. [158] (it 90d)
Phase 3 Repair: Indirect hint by in
vitro studies of the ionizing
radiation induced DNA
damage (Human vs murine
cells),with regard to the
species-specific reaction to
particles differences in repair
capacities are not investigated
Behrens et al. [159]
Phase 4 8-oxogua Tissue; rat vs. hamster R >> > H Seiler et al. [158]
Phase 4 P53 Mutation in tissue Tissue; rat vs. hamster R > H Seiler et al. [158]
Phase 4 proliferation Tissue; rat vs. hamster R >> > H Seiler et al. [158]
Carter and Driscoll [156]
Abbr.: rat, R; mouse, M; hamster, H; reduced glutathione, GSH; superoxide dismutase, SOD.
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chronic assay [158]. Phase 1 and 2 parameters (see
Table 6) were similar to the acute study on CS reported
above: rats showed stronger lung reactions with regards
to the inflammatory biomarkers than hamster. Persistent
elevated levels of 8-oxoGua in rat cells but not in ham-
ster cells in vivo demonstrate significant differences in
the development of persistent mutagenic oxidative dam-
age and proliferation and may explain the different out-
comes in rat and hamsters with respect to tumour
development (see Table 7). Importantly, both CS studies
found no proliferative response in hamster lungs after
CS exposure; thus contrasting the strong and dose-
dependent proliferative reaction in rat lungs (phase 4
effect).
The inclusion of phase 4 effects in comparing rat vs.
hamster assesses the real “point of no return reaction
level” in the cascade. The level of persistent oxidative
DNA damage, in conjunction with a continuing prolifer-
ative stimulus, appears to constitute a prerequisite con-
dition for tumour development via this secondary
genotoxic mechanism. In support and amplification of
the “Adverse Outcome Pathway” (AOP) approach de-
scribed in the Section on species-specific response
above, the data of phase 3 and 4 provide relevant infor-
mation pointing to the final adverse outcome [160].
Species-specific response to GBS: Conclusions
As can be seen from the above discussions, it is possible
to explore the species differences using the MoA, theAOP and events at the molecular level to help us better
refine the way we use translational toxicology to ex-
change experimental findings between rodent species,
primates and human responses to GBS. From the wealth
of available data, it seems too simplistic to simply as-
sume that what occurs in the rats can be assumed to
occur in humans without carefully taking into account
both critical toxicokinetic and toxicodynamic differ-
ences. This means that we have to take into account the
totality of the available information at the anatomical,
physiological, cellular and molecular level in a reliable
translational exercise. Rats have been consistently shown
to have a more sensitive response to the chronic inhal-
ation of respirable particles compared to other species,
and a unique response in relation to lung cancer. The
species-specific differences in responses are summarized
in Table 5. Thus, in agreement with ECETOC [34] we
conclude that mechanistic data are available to over-
come the default statement made by the ILSI panel in
2000 [129] and cited in [10]. This conclusion is consist-
ent with findings from studies on humans (see sections
on epidemiology and BAL studies above).
The basic assumption applied in both Model A and B
to translate rat findings to humans is one of a “species
independent” effect of GBS when expressed using spe-
cific metric scales. However, variable responses, at the
cellular and molecular levels, as well as regarding
tumour development (defense systems) are seen in mice,
hamster, rats, and primates following particle exposure.
It is thus important to ascertain how these models
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and possibly other species in order to verify the “species
independent” assumption. Such a validation exercise
should be performed prior to their use in deriving ex-
posure limit values for humans [161].
Some comments on measured occupational
exposures levels
The MAK Commission [11] derived a respirable concen-
tration limit (OEL) for GBS. The MAK Commission
made extensive use of toxicological results on CB and
TiO2. Both are leading examples of substances investi-
gated repeatedly in studies on dust effects. In the follow-
ing we present and discuss occupational exposure levels
of CB and pigmentary TiO2 in order to provide an over-
view of current or past exposure conditions at the work
place.
The CB producing industry has conducted industry-
wide exposure assessments at approximately 40 CB
manufacturing plants in North America and Europe in
support of epidemiology studies, internal and external
occupational exposure level (OEL) development, and
other industrial hygiene applications. Between 1979 and
2014 more than 13,500 inhalable TWA personal samples
have been collected, and in the period up to 2001 nearly
9,400 respirable TWA personal dust samples were col-
lected. These samples documented worker exposures by
major job class and job title [162-172]. Figure 1 presentsFigure 1 Inhalable carbon black concentration, geometric mean (GM)
(warehousing), highest exposure job classes in carbon black manufacinhalable dust exposure trends over the past 35 years for
three of the major job classes associated with CB pro-
duction in Europe and North America. Two comprehen-
sive respiratory morbidity studies were completed in
Europe and North America in the mid-1990s and early
2000s, respectively [163-168,171,172]. One of the out-
comes of these studies was that the inhalable dust frac-
tion was affirmed as the most appropriate metric for
assessing health risks in the CB producing industry
based on reported findings of bronchitis and small, but
statistically significant, decrements in one aspect of lung
function over a 40 year period.
In 2010 the ACGIH® Threshold Limit Value (TLV®)
Committee adopted a revised TLV for CB of 3.0 mg/m3
TWA, inhalable (<100 μm, aerodynamic diameter) [173].
This was the first revision to the CB TLV since its original
adoption in 1967. The ACGIH also revised its 1996 cancer
classification for CB from A4, Not Classifiable as a Hu-
man Carcinogen, to A3, Confirmed Animal Carcinogen
with Unknown Relevance to Humans. While the TLV
Committee considered animal toxicity studies related to
CB in its deliberations it also fully evaluated the extensive
worker-based epidemiology studies reported in the peer
reviewed literature [173]. Following a thorough review of
all relevant animal and human health effects information,
the ACGIH TLV Committee independently identified the
inhalable dust fraction as the most appropriate metric for
a health-based OEL for CB [173].exposures for production, maintenance, and materials handling
turing operations, 1979–2014.
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American respiratory morbidity studies and the inhal-
able metric that the TLV Committee was in the process
of adopting for CB, a low solubility low toxicity particle,
the CB producing industry ceased measurements of the
respirable dust fraction in 2001. Figure 2 presents a sum-
mary of respirable dust concentrations for the last industry-
wide exposure measurements conducted in Europe and
North America in 1995 and 2001, respectively.
It should be noted that nanostructured aggregates
and/or agglomerates have been the relevant subset of
working lifetime exposures to dusts, such as they may
have existed, within the worker populations of CB man-
ufacturers for more than 140 years. To better quantify
the nature of small particle exposures in the industry a
comprehensive particle characterization study at several
CB operations was conducted in 1999. The study con-
cluded that airborne CB particles associated with bag
filling had a size distribution starting at approximately
400 nm and that CB ultrafine particles (<100 nm, aero-
dynamic diameter) did not exceed background levels
around reactors and pelletizing operations under normal
operating conditions [174,175]. A survey of ultrafine
aerosols in various UK industries, that included a CB
producing plant, did not measure ultrafines above ambi-
ent background in the bagging operation [176].
Large hygiene and epidemiological studies were per-
formed on workers in the US and European pigmentary
TiO2 production industry (USA [92,177], Europe
[91,178]). An overview was given by Hext et al. [56]. The
European multicenter study comprised 27,522 workers
from 11 plants from six countries. Exposure reconstruc-
tion was based on personal dust measurements mainlyFigure 2 Respirable carbon black concentration, geometric mean (GM
(warehousing), highest exposure job classes in carbon black manufacperformed during the 1990s. Average respirable dust
concentrations of TiO2 dropped from about 0.3 mg/m
3
to 0.7 mg/m3 in the 1950s to current typical levels of
about 0.2 mg/m3 to 0.3 mg/m3. The maximal yearly av-
erages were reported in some jobs as 8 mg/m3. Inhalable
dust concentrations were estimated to be higher by a fac-
tor of 3.3 on the average, with a maximum at 26 mg/m3
[178]. The US study included 4,241 workers from four
production plants. In contrast to the European study, only
the long-term area samples were used. The median values
fell from 4.6 mg/m3 between 1976 and 1980 to
1.1 mg/m3 between 1996 and 2000. Packing, microniz-
ing or internal recycle workers showed a median ex-
posure at 3.0 mg/m3 in comparison to median levels
of 0.3 mg/m3 and 0.9 mg/m3 for other jobs.
As reported in the Section on epidemiology above, no
cancer excess risk has been found under these exposure
conditions. It appears that the use of epidemiological
evidence should be considered in the derivation of occu-
pational exposure limits like those of GBS. This may also
help to define the most relevant dust metric for the
measurement of work environment exposures.
Discussion
The calculations described in the MAK document [11]
on GBS are based on a number of incorrect assumptions
and calculations related to the use of lung surface area,
particle clearance rates and deposition fractions among
others which are shortcomings that affect both transla-
tional overload models (Model A and Model B) used to
derive the HEC for GBS. The methods applied do not
reflect state of the art techniques and cannot be inde-
pendently replicated since the hyper link cited by the) exposures for production, maintenance, and materials handling
turing operations in most recent respirable dust study years.
Morfeld et al. Particle and Fibre Toxicology  (2015) 12:3 Page 28 of 34MAK Commission [11] no longer leads to the program
version the Commission and Pauluhn [14] applied
(MPPD 2.0). In [14] calculations were based on a For-
tran program that is not publicly available. More import-
antly, the approaches are inconsistent as they rely on
conflicting assumptions. The resulting errors are so large
that the MAK Commission’s suggestion [11] as to how
to translate inflammation/overload findings from rats to
humans is unreliable and the OEL proposal is unsub-
stantiated. This also affects the justification of the MAK
Commission’s cancer classification [11] which is related
to humans (Carcinogen Category 4) but based on over-
load inhalation experiments with rats. This classification
relied on the validity of the proposed translational over-
load models.
The effect metrics selected by the MAK Commission
[11] and used in Pauluhn [14] did not consider particle
surface area despite toxicological evidence in favour of this
metric. No quantitative analysis was presented that could
justify why the role of particle surface area was ignored.
The MAK Commission [11] did not discuss that
workers exposed to high dust levels (coalminers) showed
no evidence of dust overload, demonstrated no lung can-
cer excess risks and that BAL findings in humans did
not replicate the PMN elevations seen in rats, even
though signs of dust effects in the BALF (change of sur-
factant lipids, and SP-A, TNF alpha increase) as well as
pneumoconiotic pathology were registered. In addition,
epidemiological studies on CB and TiO2 exposed
workers did not find a lung cancer risk that could be re-
lated to the workplace exposures. Thus, there was no
evidence presented and there is no evidence available
that overload findings in rats have relevance to humans
in cancer classification or limit value assessment apply-
ing the translational models used by the MAK Commis-
sion [11]. In an extensive epidemiological application
lung burden models did not fit any better than typical
cumulative exposure models: correlations were always
higher than 0.95 [179].
The MAK Commission [11] did not test whether the
suggested overload models reliably “translate” rat find-
ings to other species, like mice and hamsters. Because
mice and hamsters react differently to GBS than rats, we
believe that an attempt to validate the models across
these three animal species (and others) is necessary be-
fore any application to humans should be suggested in
limit value assessment [161]. We emphasize that the
endpoint chosen by the MAK Commission (markers of
inflammation and overload in the lung lavage) is invasive
and cannot be used in occupational medicine programs.
Peripheral markers should be developed and tested in
humans before these endpoints investigated in rats are
considered to be relevant for monitoring workers for
early signs of pulmonary inflammation.We explored species-species differences and con-
cluded that it seems too simplistic to assume that what
occurs in the rats occurs in humans after adjusting for
some anatomical and physiological differences. Signifi-
cant differences in the adverse outcome pathway (AOP),
at the cellular and molecular levels, as well as regarding
tumour development (defense systems) are seen in mice,
hamster, rats, and primates following particle exposure.
Reliable translational toxicology models are difficult to
develop and are too often believed to be reliable al-
though having no validation [2,68,180]. Pound et al. [68]
concluded that “the value of animal research into poten-
tial human treatments needs urgent rigorous evaluation”
and Seok et al. [2] found that “genomic responses in
mouse models poorly mimic human inflammatory dis-
eases”. So it is not surprising that our critical evaluation
of the suggested translational overload models provided
no support to the MAK Commission’s proposal for GBS
[11]. The new approach suggested does not meet general
criteria of scientific reliability: it is non-transparent, it is
inconsistent and it is not evidence-based. Moreover, it
fails in a critical area of science: using the methods pro-
posed, the results could not be reproduced.
We believe that a balanced scientific derivation of limit
value proposals for GBS and cancer classification should
use all information available and also rely on epidemio-
logical studies. This was so with the former approach
chosen by the MAK Commission [15]. They derived an
MAK value for the respirable fraction of 1.5 mg/m3 and
4 mg/m3 inhalable. The new approach [11] is based on
translational toxicology models exclusively and ignores
epidemiological evidence. A derivation based on epi-
demiological findings is suggested by other authors
and institutions who argue that a 1 mg/m3 respirable
limit may be used as a starting point for detailed dis-
cussions [9]. The Institute of Occupational Medicine
(IOM) has recommended an exposure level of 1 mg/
m3 for respirable dust and 5 mg/m3 for inhalable dust
[181]. As an input to limit value discussions in the
USA, Wheeler and Bailer [182] applied a model aver-
aging method to evaluate inhalation rat studies with
TiO2 exposures. The model average estimate of the
working lifetime mean respirable dust concentration
of TiO2 associated with a 1/1000 excess risk of lung
cancer was estimated as 9.0 mg/m3 [183]. In contrast,
CB exposures are measured as inhalable fractions at
the work places in US and Canadian production
plants according to the interpretations of epidemio-
logical studies and decisions of the US TLV commit-
tee. We note that procedures are available to estimate
threshold values from epidemiological or toxicological
data [184,185] and these methods should be applied
more often to derive limit value proposals and to dis-
cuss which metric is appropriate.
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We conclude that the problems noted in estimating a
HEC by extrapolating overload results of rats to humans
need to be addressed to ensure that OELs are based on
appropriate scientific assumptions and metrics. Further-
more, any method proposed should be reproducible by
other scientists to ensure the accuracy and reliability of
the results, especially when used for public policy such
as setting OELs.
Endnotes
aProf. Hartwig is chair of the MAK Commission and
Editor of the MAK documents.
bThe main arguments were made available to the
MAK Commission in written form in 2011 and all argu-
ments were publicly presented and discussed with repre-
sentatives of the MAK Commission at the symposium
on the new general dust limit value proposal of the
MAK Commission organized by the Committee on Haz-
ardous Substances (Ausschuss für Gefahrstoffe, AGS) of
the Federal Ministry of Labour and Social Affairs, held
in Dortmund, Germany on April 8, 2013 (http://www.
baua.de/de/Themen-von-A-Z/Gefahrstoffe/AGS/AGS-
publik-2013.html).
cThe PF&T Editors recommended, after a pre-
submission review of this manuscript, that we contact Prof.
Pauluhn to seek clarification from him on a number of
technical issues. To this end, we requested from Prof.
Pauluhn a copy of the Fortran Code and also provided Prof.
Pauluhn with a number of technical questions regarding in-
put data and other details of modelling that were not fully
explained in his publication [14]. These details were im-
portant as the model was used in the MAK Commission’s
GBS Document. Prof. Pauluhn responded to our query, but
he did not provide the requested information, partly be-
cause of contractual reasons with his previous employer.
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pulmonary disease; DNA: Desoxyribonucleic acid; ECETOC: European Center for
Toxicology and Chemicals; ECHA: European Chemicals Agency; Fe3O4: Magnetite;
FRC: Functional residual capacity; GBS: Granular biopersistent dusts (granuläre
biobeständige Stäube); GM: Geometric mean; GSD: Geometric standard
deviation; GSH: Glutathione; H: Hamster; HEC: Human equivalent concentration;
IA: Inhalability adjustment; ICBA: International Carbon Black Association;
ICRP: International Commission on Radiation Protection; ILD: Interstitial lung
diseases; IOM: Institute of Occupational Medicine, Edinburgh, UK; LSLTP: Low-
solubility low-toxicity particles; M: Mouse; MAK: MAK limit value (Maximale
Arbeitsplatz-Konzentration); MIP 2: Macrophage inflammatory protein 2;
MLE: Maximum likelihood estimates; MMAD: Mass median aerodynamic
diameter; MoA: Mode of action; MPPD: Multiple-path particle dosimetry model;
Nano-BaSO4: Nanostructured BaSO4; NOAEC: No-observed adverse-effect
concentration; NOAEL: No observed adverse-effect level; OEL: Occupational
exposure limit; OMB: Oronasal-mouth breather; ONA: Oronasal-normal
augmenter; PAH: Polycyclic aromatic hydrocarbon; PG: Phosphatidylglycerol;PI: Phosphatidylinitisol; PMresp: Deposition fraction in %; PMF: Progressive massive
fibrosis; PMN: Polymorphonuclear neutrophil; PNOC: Particles not otherwise
classified; R: Rat; RNS: Reactive nitrogen species; ROS: Reactive oxygen species;
SCOEL: Scientific Committee on Occupational Exposure Limits; SOD: Superoxide
dismutase; TiO2: Titanium dioxide; TLC: Total lung capacity; TLV®: Threshold limit
value; TNF alpha: Tumour necrosis factor alpha; TWA: Time-weighted average; U.
S. EPA: US Environmental Protection Agency; US TLV: US threshold limit value;
8-oxoGua: 8-oxo-7,8-dihydro-2′-deoxiguanosine.
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